Drug, bio-affecting and body treating compositions inventions 02/09

20090053136 - Methods of therapy and diagnosis using immunotargeting of cd84hy1-expressing cells: Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1 Protein-expressing cancer cells. Methods of immunotherapy and diagnosis... Agent: Nuvelo, Inc

20090053137 - Chelating conjugates having a substituted aromatic moiety and derivatives thereof: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and a metal coordinating moiety comprising a substituted phenyl, pyridyl, or pyrimidyl derivative.... Agent: Mallinckrodt Inc.

20090053139 - Dendrimer based compositions and methods of using the same: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing... Agent: Casimir Jones, S.c.

20090053140 - Methods of identifying genes involved in memory formation using small interfering rna(sirna): The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090053141 - Compositions and methods for magnetic resonance imaging contrast agents: The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.... Agent: Casimir Jones, S.c.

20090053142 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing amide functions allowing for the arrangement of three iodinated phenyl groups bound... Agent: Ge Healthcare, Inc.

20090053143 - Liquid inhalation formulations of dehydroepiandrosterone derivatives: Liquid pharmaceutical compositions and kits for administration to the lungs comprise a carrier and an agent for the treatment of bronchoconstriction and asthma, wherein the agent comprises a derivative of dehydroepiandrosterone having an SO2H or SO2Na group. The liquid formulations can be administered as an aerosol.... Agent: Wilson Sonsini Goodrich & Rosati

20090053144 - Reduction in bacterial colonization by administering bacteriophage compositions: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level... Agent: Hunton & Williams LLP Intellectual Property Department

20090053145 - Anti-viral compositions and methods of use in cattle: Aspects of the present disclosure relate to therapeutic RNAi compositions and methods of use thereof for treating and/or preventing disease, disorder, and/or conditions—associated with bovine respiratory syncytial virus (BRSV) infections in cattle.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090053146 - Metronidazole-based dermatological foams and emulsions for the preparation thereof: p

20090053147 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Bell, Boyd & Lloyd LLP

20090053149 - Surfactant-based antimicrobial solution for inhalation: A surfactant can be added, safely and effectively, to a drug solution containing any antimicrobial agent, such as an antibiotic like tobramycin, that is suitable for administration to the lungs via inhalation. Thus, when an aerosolized drug solution includes surfactant, Marangoni flows cause the drug particles, once deposited in the... Agent: Foley And Lardner LLP Suite 500

20090053148 - Toll like receptor modulators: The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR... Agent: Keown & Zucchero, LLP

20090053150 - Aerosol device containing at least one amps polymer and at least one fixing polymer: The invention concerns a composition packaged in an aerosol container, containing (c) at least a propellant and (b) a hair-styling composition including at least (i) one non polyurethane anionic or nonionic fixing polymer and (ii) at least one polymer comprising at least one ethylenically unsaturated monomer having a sulphonic group,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090053151 - Antibacterial peptides and analogues thereof: Antibacterial peptides and their multimeric analogues, with a wide range of action and low haemolytic activity are described. In particular, the peptide molecules exhibit a high antimicrobial activity against numerous bacterial species, with reduced cytotoxicity and a low haemolysis rate. The molecules of the invention are advantageously usable as therapeutic... Agent: Juneau Partners

20090053152 - Skin cosmetic: t

20090053154 - Mixtures of ethylhexyl p-methoxycinnamate and ethylhexyl salicylate: The present invention relates to a composition comprising or (preferably) consisting of 2-ethylhexyl p-methoxycinnamate and 2-ethylhexyl salicylate, the sum of the constituents (a) and (b) ranging from 50 to 100 wt. %, based on the total weight of the composition.... Agent: Connolly Bove Lodge & Hutz LLP

20090053153 - Polymer composite particles containing sunscreen agent and manufacturing method thereof: The present invention relates to polymer composite particles containing a sunscreen agent and a manufacturing method thereof, and more particularly, to circular-shaped polymer composite particles which are a hybrid of circular-shaped polymer particles and a sunscreen agent, drastically improve dispersion stability of particles themselves, provide excellent ultraviolet absorption performance and... Agent: Cantor Colburn, LLP

20090053155 - Cosmetic compositions containing silicone/organic copolymer: A cosmetic composition comprising at least one lipophilic liquid alkoxylated film forming polymer comprised of siloxane portions and urethane portions.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20090053156 - Hair shaping lotion: A hair shaping lotion usable as a permanent wave agent or a hair straightener which contains a multi-element mineral selected from between perlite powder and fluorite powder and which can retain the shape of hair for a long period and is reduced in the damage to the hair and the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090053159 - Anhydrous cosmetic compositions comprising at least one silicone copolymer, at least one volatile silicone, and at least one non-volatile linear polydimethylsiloxane: The present disclosure relates to anhydrous hair treatment compositions which comprise at least one copolymer based on a silicone resin and a fluid silicone, at least one linear or cyclic volatile silicone, and at least one non-volatile linear polydimethylsiloxane with a viscosity of greater than 5 cSt, wherein the at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090053158 - Pre-shave preparation with enhanced lubricity: A pre-shave composition to lubricate skin, comprising at least one polyfluoroalkyl dimethicone polymer, a volatile component to serve as a carrier to the polyfluoroalkyl dimethicone polymer, and a suspending agent to suspend the polyfluoroalkyl dimethicone polymer in the volatile component.... Agent: St. Onge Steward Johnston & Reens, LLC

20090053160 - Cosmetic composition comprising a micellar, shell cross-linked copolymer: A personal care composition comprising: i) a micellar, shell cross-linked copolymer comprising polymeric units in its centre and cross-linked polymeric units on its exterior; the polymer units in its centre having a Tg of less than 110° C. and its homopolymeric units on its exterior shell having a Tg of... Agent: Unilever Patent Group

20090053161 - Process for managing hair: The present invention is drawn to a process for managing a keratinous substrate, such as hair, involving applying onto the keratinous substrate an aqueous composition containing at least one compound chosen from a phospholipid, a polyamine, a fatty monoamine, and a fatty quaternary amine; at least one nonionic surfactant; at... Agent: L'oreal Usa/ Patent Department

20090053157 - Composition comprising a soybean oil derivative and/or a salt thereof: Composition containing an aqueous phase and an emulsifying system including at least one soybean oil derivative and/or a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090053162 - Bisphosphonate formulation: A bisphosphonate is formulated with an agent to reduce surface tension and/or reduce foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090053163 - Warming and nonirritating lubricant compositions and method of comparing irritation: This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyols and preferably an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.... Agent: Philip S. Johnson Johnson & Johnson

20090053164 - Powdery pearly lustre composition, method for the production thereof and use thereof: i

20090053165 - Method for treating damaged hair: The present invention relates to a method for treating damaged hair comprising the steps of: a) contacting the hair with a shampoo composition, the shampoo comprising: from about 5% to about 50% of an anionic surfactant; from about 0.025% to about 5% by weight of a synthetic cationic polymer having... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090053166 - Stain-proof coating composition, stain-proof coating film, substrate having coating film, stain-proof substrate, method for formation of coating film on surface of substrate, and method for stain-proofing of substrate: e

20090053167 - C-, s- and n-glycosylation of peptides: The present invention provides polypeptide conjugates wherein a modifying group such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked to the polypeptide through a glycosyl linking group. In one embodiment, the polypeptide includes a glycosylation consensus sequence, wherein glycosylation occurs at an aromatic amino acid... Agent: Morgan, Lewis & Bockius LLP (sf)

20090053172 - Heterocyclic compounds as ccr5 antagonists: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090053170 - Human prostate cell lines in cancer treatment: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumour specific antigens (“TSAs”) and/or tumour associated antigens (“TAAs”) having shared identity with antigens in a targeted tumour. In... Agent: Proskauer Rose LLP

20090053169 - Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same: The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20090053171 - Treatment of cellular proliferative disorders: Disclosed are composition and methods for treating cellular proliferative disorders.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090053168 - Treatments of b-cell proliferative disorders: The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.... Agent: Clark & Elbing LLP

20090053174 - Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus: There are provided an ejection liquid that contains at least one of proteins and peptides and can be ejected stably by an ink jet system, and a method and apparatus for ejecting a liquid containing at least one of proteins and peptides using the ejection liquid. A specific amine is... Agent: Fitzpatrick Cella Harper & Scinto

20090053173 - Long acting human interferon analogs: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have... Agent: Yi Li

20090053175 - Substitute pyrrolidine derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090053176 - New combination 937: The present invention related to a combination of (a) a compound which is a MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a compound or a pharmaceutically acceptable salt thereof, which is used in the treatment and/or prevention of PD or Multiple Sclerosis. The invention further relates to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090053177 - Protein-polymer conjugates: This invention relates to protein-polymer conjugates described in the specification. Also disclosed are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090053178 - Use of herpes vectors for tumor therapy: Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV)... Agent: Foley And Lardner LLP Suite 500

20090053185 - Coagulation factor x polypeptides with modified activation properties: The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090053184 - Compositions comprising t cell receptors and methods of use thereof: Nucleic acids encoding antitumor TCRs recognizing MART-1, NY-ESO-1, and melanoma gp100 peptides; vectors and cells comprising the same; and methods of using the foregoing.... Agent: Leydig, Voit & Mayer, Ltd.

20090053186 - Therapy for primary and metastatic cancers: The present invention relates to compositions and methods for ablating tumor cells in a subject having at least one tumor site. More specifically, the method comprises contacting the tumor cells in at least one tumor with a lytic agent in vivo, under lytic conditions, forming a treated tumor; and applying... Agent: T. Ling Chwang Jackson Walker L.L.P.

20090053179 - Method for using liberated dormant bacteriophage and environmental stress to reduce infectious bacteria: A method for obtaining bacteriophages by stressing bacteria. The method involves isolating bacteria, propagating the bacteria, exposing the bacteria to at least one environmental stressing agent to induce excision of bacteriophage that are present in the bacterial genome. Multiple or individual environmental stressing agents may be applied. These liberated bacteriophages... Agent: Knoble, Yoshida & Dunleavy

20090053182 - Endometrial stem cells and methods of making and using same: The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090053181 - Modulation of cells: The present invention is directed to methods which can be used to test agents for their ability 5 to modulate cell proliferation, differentiation and other biological activities of target cells such as stem cells. In addition, the invention is also directed to methods for modulating a biological activity of target... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090053180 - Tandem cardiac pacemaker system: This invention provides pacemaker systems comprising (1) an electronic pacemaker, and (2) a biological pacemaker, wherein the biological pacemaker comprises a cell that functionally expresses a chimeric hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channel at a level effective to induce pacemaker current in the cell. The invention also provides related biological... Agent: Kenyon & Kenyon LLP

20090053183 - Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090053187 - Agent exhibiting bactericidal action with respect to vegetative and spore cells bacillus anthrasis, anthrax preventing and treating method: The invention relates to the field of biotechnology, medicine, and veterinary and can be used for anthrax prevention and treatment. The proposed drug has a bactericidal effect on vegetative and spore cells of Bacillus anthracis and comprises a bacteriolytic complex produced by bacterial strain Lysobacter sp. XL 1. The bacteriolytic... Agent: Ladas & Parry LLP

20090053188 - Method of preventing reduced feed intake in animals and treatment of disease conditions: The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising... Agent: Quarles & Brady LLP

20090053189 - Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof: The present invention is based, at least in part, on the identification of molecules involved in the differentiation and/or activity of osteoblasts and osteoclasts. Accordingly, the present invention provides methods of identifying modulators of bone formation, mineralization, and/or osteoclastogenesis and methods for treating disorders that would benefit from modulation of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090053190 - Treatment of macular degeneration with adp-ribosyl transferase fusion protein therapeutic compositions: The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4... Agent: Ogilvy Renault LLP

20090053191 - Phospholipases, nucleic acids encoding them and methods for making and using them: The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.... Agent: Verenium C/o Mofo S.d.

20090053192 - Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof: Disclosed herein are tissue-nonspecific alkaline phosphatase (TNAP) activators and uses thereof for promoting bone mineral deposition.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20090053193 - Use of factor viia for the treatment of burn trauma: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of burn trauma.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090053138 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics: Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20090053195 - Biomarkers for acute graft rejection: Methods are disclosed for the early non-invasive diagnosing of acute rejection (AR) in a transplanted subject, monitoring AR in a transplanted subject at risk of developing AR, preventing, inhibiting, reducing or treating AR in a transplanted subject, or identifying agents for use in the prevention, inhibition, reduction or treatment of... Agent: Novartis Corporate Intellectual Property

20090053209 - Blockade of pin1 prevents cytokine production by activated immune cells: The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP/warf

20090053196 - Chn-1/chip-antagonists for the treatment of muscular diseases: The present invention relates to a pharmaceutical composition comprising an inhibitor/negative regulator/antagonist of the mammalian ortholog of Caenorhabditis elegans CHN-1 and/or of the human CHIP (carboxyl-terminus of Hsc70 interacting protein). Furthermore, the use of said inhibitor/negative regulator/antagonist in medical and pharmaceutical settings is described. In addition, screening methods and tools... Agent: Foley And Lardner LLP Suite 500

20090053198 - Cytokine induction of selectin ligands on cells: Methods and compositions for treating cells with cytokines are provided herein.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090053204 - Functional genomic pore assay for mixed cell populations: A method of assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with... Agent: Quarles & Brady LLP

20090053201 - Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral... Agent: Baker Botts L.L.P.

20090053203 - Metal-binding therapeutic peptides: The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent: Morrison & Foerster LLP

20090053200 - Method for retarding unhealth manifestations brought by ageing of human beings: According to the invention this task is solved by administration into the blood circulation of the agent which inactivates extracellular blood plasma DNA; the extracellular blood DNA inactivating agent can be embodied in the form of an extracellular blood plasma DNA destroying agent; said extracellular blood plasma DNA destroying agent... Agent: Patent, Copyright & Trademark Law Group

20090053194 - Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent: A method of treatment for treating, preventing, inhibiting or reducing a biological or immunological response to a reactive chemical agent, biological agent or toxin, by tissue of a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a response-inhibiting agent including... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090053207 - Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas: The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases.... Agent: Fulbright & Jaworski L.L.P.

20090053208 - Methods and systems for improving tissue perfusion: Methods and systems are disclosed for treating injured and/or ischemic tissue by delivering a platelet composition which induces neovascularization in the tissue and improves tissue perfusion.... Agent: Medtronic Vascular, Inc.IPLegal Department

20090053206 - Novel synthetic agonists of tlr9: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.... Agent: Keown & Zucchero, LLP

20090053202 - Peptide fragment of lyve-1 and antibody against the same: e

20090053205 - Stabilized immune modulatory rna (simra) compounds: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.... Agent: Keown & Zucchero, LLP

20090053199 - Stable dairy components effective for fat loss: The present invention relates to methods comprising administering to individuals regulating body weight calcium-containing fresh whey products in an amount effective to manage body mass, by inducing weight and/or fat loss, preventing weight and/or fat gain, increasing the metabolic consumption of adipose tissue, and/or maintaining muscle mass.... Agent: Venable LLP

20090053197 - Transfer factor compositions and methods: Compositions are provided comprising transfer factor alone or combined with an antibody. The antibody may be contained in an antibody fraction. The transfer factor and/or the antibody or antibody fraction may be lyophilized. Also provided are formulations further comprising glucans, as well as additional optional components. Also provided are methods... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090053210 - Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals: The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090053215 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20090053218 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent... Agent: Edell, Shapiro & Finnan, LLC

20090053217 - Human anti-vegf polyclonal antibodies and uses thereof: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.... Agent: Pearl Cohen Zedek Latzer, LLP

20090053214 - Humanised anti-mag antibody or functional fragment thereof: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090053212 - Humanized anti-human osteopontin antibody: The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090053221 - Immune response enhancing glucan: This invention discloses a composition for enhancing the protective immunity in a subject, comprising an effective amount of a β-glucan and a vaccine, wherein the β-glucan enhances the immune response of the vaccine against cancer or infectious agents. The infectious agents can be viruses, fungi, bacteria or parasites. In one... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090053219 - Methods and compositions for increasing alpha-l-iduronidase activity in the cns: Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific... Agent: Wilson Sonsini Goodrich & Rosati

20090053220 - Methods and compositions for the inhibition of hiv infection of t cells: The present invention is based upon the surprising discovery that exposure of a non-resistant HIV to a first entry inhibitor, such as an anti-CD4 antibody or a co-receptor inhibitor, which like all current HIV drugs selects for mutations that result in a resistant HIV, surprisingly results in HIV viruses much... Agent: Jones Day

20090053222 - Methods of treating cancer by administering antibodies to cd200: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing... Agent: Bereskin And Parr

20090053216 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20090053213 - Anti-gm-csf antibodies and uses therefor: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be... Agent: Foley And Lardner LLP Suite 500

20090053211 - Optimized fc variants: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20090053223 - Expression-enhanced polypeptides: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated... Agent: Fulbright & Jaworski L.L.P.

20090053224 - Lox and loxl2 inhibitors and uses thereof: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a... Agent: Wilson Sonsini Goodrich & Rosati

20090053225 - Recombinant antibodies against cd55 and cd59 and uses thereof: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising... Agent: Cooper & Dunham, LLP

20090053226 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090053227 - Prostate specific genes and the use thereof in design of therapeutics: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2.... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090053230 - Anti-ox40l antibodies and methods using same: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20090053228 - Lawsonia intracellularis subunit vaccines: The present invention relates i.a. to nucleic acids encoding novel Lawsonia intracellularis proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the... Agent: Intervet/schering-plough Animal Health Patent Department

20090053229 - Methods of treating conditions involving neuronal degeneration: The invention provides methods for treating conditions of the eye involving death or degeneration of retinal ganglion cells, including glaucoma, by the administration of Nogo receptor-1 antagonists.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090053232 - Modulation of synaptogenesis: The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an α2δ subunit of a calcium channel.... Agent: Morrison & Foerster LLP

20090053231 - Optical disc apparatus: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental... Agent: Fish & Richardson PC

20090053233 - Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations: The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of... Agent: Birch Stewart Kolasch & Birch

20090053234 - Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphavbeta3 antogonists in combination with other prophylactic or therapeutic agents: The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering... Agent: Medimmune, LLC Jonathan Klein-evans

20090053235 - Use of alpha-toxin for treating and preventing staphylococcus infections: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines... Agent: Foley And Lardner LLP Suite 500

20090053236 - Use of combination of anti-angiogenic substance and c-kit kinase inhibitor: The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity.... Agent: Dickstein Shapiro LLP

20090053237 - Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections: The present invention is drawn to a penicillin-binding protein expressed by Neisseria meningitidis, or a fragment, or a variant, or a variant fragment thereof, or nucleic acids encoding them, or antibodies or antibody fragments directed against them, as medicaments or in pharmaceutical compositions. The invention is also directed to the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090053239 - Acacs as modifiers of the igf pathway and methods of use: Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090053240 - Novel immunoglobulin insertions, deletions and substitutions: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.... Agent: Morgan, Lewis & Bockius, LLP

20090053241 - Pdgfrbeta-specific inhibitors: The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090053238 - Stabilized high concentration anti-integrin alphavbeta3 antibody formulations: The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin αVβ3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In... Agent: Medimmune, LLC Jonathan Klein-evans

20090053242 - Thrombopoietic compounds: The invention relates to the use of compounds, especially peptides or polypeptides, that have thrombopoietic activity, and pegylated forms thereof. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Marshall, Gerstein & Borun LLP

20090053243 - Anti-igsf4 antibody and utilization of the same: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and... Agent: Edwards Angell Palmer & Dodge LLP

20090053244 - Modified vaccinia virus strains for use in diagnostic and therapeutic methods: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.... Agent: Bell, Boyd & Lloyd LLP

20090053245 - Pharmacokinetics and efficacy of anti-angiogenic drugs and drugs treating diseases of the blood: A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090053247 - Biological materials and uses thereof: The invention provides a compound comprising a photosensitising agent coupled to a carrier molecule with a minimum coupling ratio of 3:1 wherein the carrier molecule has a binding specificity for a target cell. There is also provided a process of conjugation comprising the use of a first and second aprotic... Agent: Fish & Richardson PC

20090053246 - Immunoglobulin fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same: Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by... Agent: Seed Intellectual Property Law Group PLLC

20090053248 - Compositions and methods for transepithelial molecular transport: The invention relates to fragments of Clostridium botulinum HC that can be linked with an entity (e.g., an antigen, a particle, or a radionuclide) and used to deliver the entity across a non-keratinized epithelial membrane of an animal. The fragments are useful, for example, for making vaccines, antidotes, and anti-toxins... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090053252 - Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a... Agent: Connolly Bove Lodge & Hutz, LLP

20090053251 - Dendritic cell compositions and methods: Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced... Agent: Merix Bioscience, Inc.

20090053250 - Immune modulating oligonucleotides in connection with chemotherapeutic measures: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090053253 - Process for the measurement of the potency of glatiramer acetate: The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.... Agent: Cooper & Dunham, LLP

20090053249 - Specific inhibition of autoimmunity and diseases associated with autoantigens: The present invention provides compositions and methods for specifically inhibiting host immune responses against autoantigens. In particular, compositions and methods combining CD8 polypeptide expression with autoantigen expression or presentation are described for specifically inhibiting the humoral and cellular components of the host immune response to autoantigens.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090053255 - Anti-arthropod vector vaccines, methods of selecting and uses thereof: The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.... Agent: Klarquist Sparkman, LLP

20090053254 - Recombinant human alpha-fetoprotein as an immunosuppressive agent: Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.... Agent: Clark & Elbing LLP

20090053256 - Poxvirus methods and compositions: Methods and compositions for inducing immune responses against poxviruses are disclosed. The compositions include nucleic acids that encode modified vaccinia and variola antigens. Compositions that include recombinant vaccinia and variola polypeptides are also disclosed.... Agent: Fish & Richardson PC

20090053257 - Replikin peptides and uses thereof: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease.... Agent: Kenyon & Kenyon LLP

20090053258 - Assays for diagnosis of tuberculosis and uses thereof: The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090053259 - Vaccines and methods for treatment or prevention of gram negative bacterial infection in a vertebrate subject: Methods for the treatment or prevention of Gram negative bacterial infection in a vertebrate subject are provided. The methods provide administering an antagonist of bacterial flagellar protein biosynthesis to the vertebrate subject in an amount effective to reduce or eliminate the bacterial infection. Methods for the treatment or prevention of... Agent: Fenwick & West LLP

20090053260 - Algae essence nucleic acid fluid concentration preparation method: The present invention discloses an alga essence nucleic acid fluid concentration method, to apply the leaching function principle with the operation of freezes defreeze to achieve the goal of extract nucleic acid from the concentrated chlorella. Because of above operation steps with this invention, it will obtain better density of... Agent: Wpat, PC

20090053261 - Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications: Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the “free” protein antigen. The 2100 coat proteins comprising the rod-shaped capsid of Tobacco mosaic virus (TMV) can accommodate... Agent: Wyatt, Tarrant & Combs, LLP

20090053262 - Combination vaccine for poultry: The present invention relates to a combination vaccine for the protection of poultry against Ornithobacterium rhinotracheale, to the use of a live over-attenuated Ornithobacterium rhinotracheale strain and a live attenuated poultry virus for the manufacturing of such a combination vaccine, to methods for the preparation of said combination vaccine and... Agent: Intervet/schering-plough Animal Health Patent Department

20090053263 - Inhibitors of enveloped virus infectivity: The present invention relates to treatment of infection by enveloped viruses through the use of papain-like cysteine protease inhibitors and kits thereof. Specifically, methods for treatment of filoviruses as well as other enveloped viruses such as Nipah, in particular using cathepsin inhibitors are described.... Agent: Wolf Greenfield & Sacks, P.C.

20090053264 - Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals: In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus... Agent: Jones Day

20090053265 - Antigenic peptides and their use: This invention relates generally to the field of pathogen peptidic antigens and their use, for example, for the preparation of a vaccine against said pathogen. More specifically, the present invention relates to an antigenic peptide deriving from Plasmodium species sequences, and includes antibodies and methods of producing and using same.... Agent: Harness, Dickey & Pierce, P.L.C

20090053266 - Apicomplex vaccine strains of a family of sarcocystidae: The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC1 and MIC3 adhesins and to the use thereof for a vaccine.... Agent: Morgan Lewis & Bockius LLP

20090053270 - Cosmetic for eyelashes: The cosmetic for eyelashes according to the present invention is capable of simply imparting a good curl-up effect to eyelashes, is free from formation of lumps upon coating, and can exhibit a high moisture resistance and a high curl retention effect during use as well as a beautiful finish. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090053267 - Dentifrice composition containing silicone oil beads: Dentifrice composition and method of using such dentifrice composition to ameliorate dry mouth, where the dentifrice composition includes an orally acceptable vehicle having distributed therein silicone oil beads, and wherein the dentifrice composition has a viscosity of at least about 20,000 centipoise.... Agent: Colgate-palmolive Company

20090053272 - Method for producing polymer nanoparticles: A process for the preparation of polymeric nanoparticles, in which an emulsion of monomers and additional components is produced in a nonsolvent and subsequently illuminated, makes it possible to prepare polymeric nanoparticles which comprise, in a desired concentration, an effect substance, for example a dye, and/or an active substance, for... Agent: Connolly Bove Lodge & Hutz, LLP

20090053268 - Nanoparticle modified lubricants and waxes with enhanced properties: The present invention provides compositions and products, such as waxes and lubricants, comprising a plurality of nanoparticles dispersed in a continuous phase comprising a vegetable oil derived material, such as one or more vegetable oils or a synthetic product derived from one or more vegetable oils. Incorporation of nanoparticles in... Agent: Greenlee Winner And Sullivan P C

20090053269 - Powder-containing transparent solid cosmetic preparation: The present invention provides a novel solid powder which has transparency in its appearance, and has excellent usability and, in addition, excellent feeling of use such as dry feeling and fresh light feeling without sticky feeling during application. It is achieved by a solid powder cosmetic comprising: (A) 25 to... Agent: Foley And Lardner LLP Suite 500

20090053271 - Reverse-phase microcapsules for actice ingredients, simplified process of manufacture thereof and combined formulation wdg- cs,zc, ec-sc, and cx: This invention relates to microcapsules and processes of microencapsulation of water soluble or water dispersible compounds by reverse-phase microencapsulation, referred to agrochemicals but not as a limiting feature, and how to combine them with other oil soluble or oil dispersible compounds in suitable formulations for agriculture, in a industrially viable... Agent: James Murphy One Arts Plaza

20090053274 - Delivery system for a medicament or well-being enhancing composition: A delivery system for a medicament or well-being enhancing composition, comprising a flexible member, means for attaching the flexible member to fabric to form a pocket and an absorbent pad for impregnation with the medicament or well-being enhancing composition arranged such that when the flexible member is attached to a... Agent: Knobbe Martens Olson & Bear LLP

20090053273 - Topical medication garment and system and method for providing topical medication: A topical medication garment, a system and a method provide topical medication. An impermeable garment may allow the topical medication to maintain contact with the skin of the user. The garment may prevent the topical medication from absorption into clothing or the undergarment itself. The entirety of the garment may... Agent: Patents+tms, P.C.

20090053275 - Foam/spray producing compositions and dispencing system therefor: By providing a therapeutic agent in a mixture with water in combination with at least one selected from the group consisting of surfactants, excipients, thickening agents, and water, a unique, improved, liquid based foam or spray and/or gel producing formulation is realized which is useable for a wide variety of... Agent: Melvin I. Stoltz

20090053276 - Injectable hydrogel compositions: In accordance with one aspect of the invention, injectable compositions are provided, which contain temperature-sensitive hydrogel particles. The hydrogel particles may be provided in dry form, or they may be provided in hydrated form in an aqueous fluid. The temperature-sensitive hydrogel particles may have an upper critical solution temperature (UCST)... Agent: Mayer & Williams PC

20090053278 - Anti-microbial compositions and devices and methods of using the same: Embodiments of the present invention include medical devices that are coated with an antimicrobial peptide-based coating. Further embodiments include methods of coating the devices with the antimicrobial peptide-based coating, and treating a subject with the coated medical devices to prevent or relieve bacterial infections in the subject.... Agent: Pepper Hamilton LLP

20090053282 - Bone grafting method and kit: Bone grafting methods involving harvesting at least of the following types of cells: osteoblasts, adult stem cells and primitive mesenchymal cells and applying these cells to a site intended for a bone graft in combination with the application of a suitable matrix material, where the matrix material is an allograft,... Agent: Crowell & Moring LLP Intellectual Property Group

20090053277 - Cell sheet containing mesenchymal stem cells: Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were... Agent: Birch Stewart Kolasch & Birch

20090053280 - Coating stents with cyclic rgd peptides or mimetics: It is an object of the present invention to overcome certain disadvantages of stents, such as drug eluting stents. In particular, it is an object to provide a stent with improved re-endothelialization ability and/or simultaneous reduced rate of restenosis and/or minimal or no inflammatory potential.... Agent: Wolf Greenfield & Sacks, P.C.

20090053283 - Compositions and methods for treating diseases: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers... Agent: Wilson Sonsini Goodrich & Rosati

20090053281 - Embolization: Articles and methods that include a particle having a maximum dimension of at most 5,000 microns, and an embolic coil capable of binding to the particle, are disclosed.... Agent: Fish & Richardson PC

20090053279 - Tissue regenerative composition: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.... Agent: Barnes & Thornburg LLP

20090053284 - Medical devices for use in the surgical treatment of hyperproliferative diseases affecting the spinal cord: Provided herein are new methods for the treatment of hyperproliferative diseases affecting the spinal cord, including the use of biodegradable polymers to treat spinal cord tumor recessing, i.e., to patch open zones left by spinal tumor removal. Biocompatible polymeric materials are tailored to fill areas previously occupied by tumors, e.g.,... Agent: Saul Ewing LLP (harrisburg) Attn: Patent Docket Clerk

20090053285 - Medicament carrier composition and method of forming a film therefrom: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary... Agent: Howard & Howard Attorneys, P.C.

20090053286 - Products and methods for maintaining or increasing ceramide levels in skin: Disclosed are methods and products such as wet wipes and absorbents capable of providing a skin health benefit when utilized in the intended fashion. More specifically, the products described herein comprise an agent, such as a botanical extract, which is capable of increasing the activity of sphingomyelinase according to a... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090053287 - Porous dressing: A porous dressing is provided. The porous dressing includes a polymeric layer, a pharmaceutically active ingredient and a metal oxide. The polymeric layer has a porosity and a bio-compatibility, and the pharmaceutically active ingredient and the metal oxide distribute in one selected from a group consisting of in the polymeric... Agent: Volpe And Koenig, P.C.

20090053288 - Hemostatic woven fabric: The present invention is directed to a woven fabric having the modified crowsfoot weave pattern shown in FIGS. 2A and 2B. The present invention is directed to a woven fabric comprising about 65 wt % fiberglass yarn and about 35 wt % bamboo yarn, the woven fabric (1) being about... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090053289 - Kit for the treatment of a corn or callus: The present invention is a kit for use by a person to apply a daily treatment of medication and therapy to remove a corn or callus from the person's skin while providing maximum comfort to the person and minimal damage to healthy skin. In one embodiment, the kit comprises a... Agent: Adams Intellectual Property Law, P.A.

20090053290 - Transdermal drug delivery compositions and topical compositions for application on the skin: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a... Agent: Christie, Parker & Hale, LLP

20090053294 - Anti mineralocorticoid therapy of infection: Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090053302 - Cancer treatments: The present invention relates to liposome comprising encapsulated oxaliplatin and methods for making encapsulated oxaliplatin. The invention also relates to liposomes comprising oxaliplatin and another anticancer drug. The liposomes of the invention are useful in cancer treatments.... Agent: Brooks Kushman P.C.

20090053298 - Compositions and methods for inhibiting car gene expression by rna interference: The present invention provides short interfering ribonucleic acid (siRNA), compositions and methods for inhibiting the CAR gene expression simply and rapidly, which can be used for evaluating toxicity of a chemical substance.... Agent: Panitch Schwarze Belisario & Nadel LLP

20090053297 - Compositions and methods for less immunogenic protein-lipid complexes: The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phosphatidyl ethanolamine.... Agent: Hodgson Russ LLP The Guaranty Building

20090053291 - Fusion proteins comprising hiv-1 tat and/or nef proteins: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090053296 - Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin: The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia... Agent: Fulbright & Jaworski L.L.P.

20090053299 - Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery: The present invention is in the fields of drug delivery, and specifically, cationic liposome-based vaccines. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of molecules to induce immune responses against viral antigens or to treat or prevent viral diseases.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090053300 - Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent: Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a... Agent: Leydig Voit & Mayer, Ltd

20090053292 - Moraxella catarrhalis protein, nucleic acid sequence and uses thereof: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides... Agent: Foley And Lardner LLP Suite 500

20090053293 - Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids: The present invention provides a nano-micellar preparation containing vinca alkaloids antitumor agent for intravenous injection, which cincludes a therapeutically effective amount of vinca alkaloids antitumor agent (vinblastine, vincristine, vindesine and vinorelbine), a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament... Agent: Knobbe Martens Olson & Bear LLP

20090053295 - Regulatable fusion promoters: Fusion promoters are described that combine a RNA polymerase III basal promoter and regulatory elements from RNA polymerase II regulatory regions, and which provide specific regulation of expression from the promoter. Such fusion promoters are useful, for example, for expressing RNAi agents in vivo.... Agent: Fish & Richardson PC

20090053301 - Silicone vesicles containing actives: A process is disclosed for preparing a hydrophobic active loaded vesicle composition by admixing a hydrophobic active to a pre-formed silicone vesicle dispersion. The silicone vesicle compositions are useful in a variety of personal and healthcare compositions.... Agent: Dow Corning Corporation Co1232

20090053304 - Composition and method of producing a taste masking formulation of laxatives for bowel cleaning preparation prior to colonoscopy: This invention relates to a solid taste masking formulation of laxatives which can be dispersed in water for oral use for bowel cleaning preparation prior to colonoscopy procedures. This invention also relates to the methods to produce the taste masking laxative formulations.... Agent: Jinling Chen

20090053303 - Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes: A medical food and/or nutritional supplement for oral administration by mammals includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components,... Agent: Hogan & Hartson LLP

20090053305 - Pharmaceutical formulations: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.... Agent: Paul D. Yasger Abbott Laboratories

20090053307 - Immediate-release therapeutic systems for improved oral absorption of 7-[(e)]-t-buty-loxyminomethyl] camptothecin: A pharmaceutical composition comprising a camptothecin as active ingredient is herein described. In particular immediate-release therapeutic systems are described for the improved oral absorption of 7-[(E)-t-butyloxyminomethyl] camptothecin, comprising a matrix consisting of liquid amphiphilic substances or having a melting point lower than 60° C., in which the active principle is... Agent: Lucas & Mercanti, LLP

20090053306 - Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto: The present invention relates to certain pharmaceutical compositions of a 5-HT2A serotonin receptor modulator and methods for preparing pharmaceutical composition related thereto. The pharmaceutical compositions are useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood... Agent: Fish & Richardson P.C.

20090053308 - Release-control composition: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for... Agent: Edwards Angell Palmer & Dodge LLP

20090053309 - Adhesive compositions for the treatment of xerostomia: Compositions and methods for the treatment of xerostomia are disclosed herein. Methods for making the compositions are also disclosed herein. The compositions are designed for individuals having the physiologic ability to salivate but who do not salivate in sufficient quantity to satisfy their personal comfort level of oral hydration. The... Agent: Pabst Patent Group LLP

20090053310 - Novel sustained release dosage form: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.... Agent: Merchant & Gould PC

20090053312 - Methodology and composition for a skin lubricant: One possible embodiment of the invention could be a method of lubricating human skin comprising of the following steps, but not necessarily in the order shown: providing a composition of a gel formed from cross-linking siloxane polyethers, the gel being further micronized in one or more low viscosity, silicone fluids;... Agent: Long & Chybik

20090053311 - Pharmaceutical compositions for treating or preventing bone conditions: Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.... Agent: Zhaoyang Li, Ph.d Squire, Sanders And Dempsey L.L.P.

20090053313 - Process for the preparation of a polymeric hydrogel based on a highly purified polyvinylalcohol and uses thereof: The present invention relates to the preparation of a completely biocompatible and injectable, crosslinked polymeric hydrogel based on a polyvinyl alcohol. Said polymer, which is produced in a highly purified form, proved particularly suitable for the preparation of a filler to be employed in medicine and cosmetics, for the purpose... Agent: Pearne & Gordon LLP

20090053316 - Nanoclusters for delivery of therapeutics: The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising... Agent: Holland & Hart, LLP

20090053314 - Submicronization of proteins using supercritical fluids: An apparatus and a method for the submicronization of proteins using supercritical fluids is provided for feeding the supercritical fluid and feeding a protein solution using a precipitation vessel with a taper shape at its lower part, in which the precipitation vessel accommodates the supercritical fluid and the protein solution... Agent: The Rafferty Patent Law Firm

20090053315 - Thermo-kinetic mixing for pharmaceutical applications: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one... Agent: Chalker Flores, LLP

20090053317 - Microparticulate systems for the oral administration of biologically active substances: The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals... Agent: Steinfl & Bruno

20090053318 - Forming embolic particles: Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed.... Agent: Fish & Richardson PC

20090053319 - Sore throat relief composition and method of producing same: The present invention provides a sore throat relief composition and a method of producing the composition comprising oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients, combined with vegetable glycerin, purified water, spearmint oil, wild cherry bark, clove honey, and ascorbic acid for fully relieving and preventing... Agent: Amin Hallihan, LLC

20090053320 - Disease and pest control agent containing dissolved microbubles consisting of oxygen and ozone: The present invention relates to systems and methods for producing disease and pest control agent for plants and crops containing dissolved oxygen and ozone. This present invention of disease and pest control agent for plants and crops containing dissolved microbubbles of oxygen and ozone consists of 0.3-40 μm pore size... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090053321 - Vaginal rinse with enhanced bacteriocidal activity: There are provided vaginal rinse compositions, consisting essentially of :a) 1-20 wt % of a mucosally acceptable peroxide, b) 0.5-15 wt % of a mucosally acceptable sulfate, bisulfate, pyrosulfate salt of an inorganic cation or mixtures thereof, and c) water to 100 wt %. There are further provided methods of... Agent: Omri M. Behr

20090053322 - Rare earth metal compounds, methods of making, and methods of using the same: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the... Agent: Morrison & Foerster LLP

20090053323 - Aqueous disinfectants and sterilants including transition metals: The present invention is drawn to disinfectant or sterilant compositions, which are human safe, e.g., food grade or food safe. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001... Agent: Thorpe North & Western, LLP.

20090053324 - Calcium supplements: A composition comprising at least 5%, by weight, of calcium and at least 5%, by weight, of magnesium wherein the composition is derived from marine algae.... Agent: Nixon & Vanderhye, PC

20090053326 - Compositions, systems, and/or methods involving chlorine dioxide (\"clo2\"): Certain exemplary embodiments can provide a composition of matter comprising chlorine dioxide dissolved in acetic acid. When stored, a concentration of the chlorine dioxide in the composition of matter can be retained, with respect to an initial concentration of chlorine dioxide in said composition of matter, at, for example, greater... Agent: Michael N. Haynes

20090053325 - Method of controlling floating virus infection: A method of controlling floating virus infection. The method includes the step of: supplying chlorine dioxide gas into a space where floating virus can be present by a gas concentration which allows the animal to live or stay, but deactivates the virus.... Agent: Buchanan, Ingersoll & Rooney PC

20090053327 - Concentrated aqueous bromine solutions and their preparation: This invention provides concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by... Agent: Albemarle Corporation Patent Department

20090053328 - Nitric oxide enhancing glutamic acid compounds, compositions and methods of use: The invention provides novel compositions and kits comprising at least one nitric oxide enhancing glutamic acid compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating... Agent: Wilmerhale/nitromed

20090053329 - Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics: Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the... Agent: Knobbe Martens Olson & Bear LLP

20090053332 - Compositions for diabetes treatment and prophylaxis: Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that optionally contain a non-metabolizable polysaccharide such as the exudate of Sterculia urens.... Agent: Olson & Cepuritis, Ltd.

20090053331 - Hands and feet sanitizing system: A sanitizing system is provided which includes an antibacterial liquid composition formulated to sanitize and deodorize the hands, feet, and other areas of the body. The antibacterial liquid composition is adapted to be dispensed from a pump dispenser as a topical spray.... Agent: P. Jeff Martin Of The Mcgougan Law Firm, LLC

20090053330 - Process for preparation of rhus verniciflua extracts having excellent anti-cancer activity and anti-cancer pharmaceutical composition containing the same: Provided is a process for preparation of a Rhus verniciflua extract, comprising extracting allergen-removed Rhus verniciflua with a soluble solvent, thereby obtaining an extract, subjecting the thus-obtained extract to ultrafiltration to remove high-molecular weigh substances, concentrating and drying the resulting material, thereby obtaining extract powder and irradiating far-infrared to the... Agent: Ipla P.A.

20090053333 - Treatment of vegetation liquors derived from oil-bearing fruit: The present invention relates to processes for the treatment of liquors derived from oil-bearing fruit, for example from oil palm fruit, and to products therefrom. Typically a process involves removal of undissolved solids, oleaginous parts, colloids and higher weight molecules from the vegetation liquor to give an aqueous fraction containing... Agent: Foley & Lardner LLP

20090053334 - Ghrelin production promoter: The objectives are to find a substance or a composition capable of promoting the production of ghrelin with physiological activities such as growth hormone secretion effect, and to provide a pharmaceutical comprising it as the active ingredient. The pharmaceutical is a ghrelin production promoter comprising Rikkunshi-to as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090053335 - Herbal compositions for the inhibition of human immunodeficiency virus (hiv): The invention provides a herbal composition for the inhibition of HIV, comprising an organic extract of Hedyotis diffusa (Oldenlandia diffusa), an organic solvent extract of Scutellaria barbata or Scutellaria rivularis, an organic solvent extract of Lonicera japonica or Lonicera confusato, an organic solvent extract of Prunella vulgari and an organi... Agent: Wpat, PC Intellectual Property Attorneys

20090053336 - Method and formulations for treating candidiasis using morinda citrifolia: The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract,... Agent: Kirton And Mcconkie

20090053337 - Composition and method of improving skin barrier function of compromised skin: A composition and method of improving skin barrier function of compromised skin by applying onto the compromised skin a composition containing: (a) a complex comprised of a metal-copper-antioxidant botanical pigment; (b) an extract of pinus pinaster bark; (c) an extract of pilewort; and (d) a carrier vehicle.... Agent: L'oreal Usa/ Patent Department

20090053339 - Composition for treatment of menopause: A method of using an herbal extract of the a mixture of: Herba Scutellaria barbata, Radix Sophora subprostratae, Radix Anemarrhena Semen Glycine sojae, Radix Glycyrrhiza, Rhizoma Rhei, Fructus Tritici levis, Radix Astragali, Radix Rehmania, Fructus Ligustri lucidi, Semen Zyziphi spinosa, Plumula Nelumbinis, Poria cocos, Rhizoma Alismatis, Cortex Moutan radicis, Fructus... Agent: Wilson Sonsini Goodrich & Rosati

20090053338 - Method for the preparation of phytoprogestogenic extracts from rhizoma ligusticum chuanxiong and uses thereof: A method of extracting phytoprogestogenic compounds from herbs and their use in preparing a medicament for treating humans requiring progesterone replacement or supplement. Assay systems to quantify progesterone and progestogenic receptor activity and a method for assembling a kit for the assays are also provided.... Agent: Jackson Walker LLP

20090053341 - Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present... Agent: Michael F. Krieger Kirton & Mcconkie

20090053340 - Therapeutic uses of tomato extracts: e

20090053342 - Preparation of microbial oil: The present invention provides a process for the production of a microbial oil comprising culturing a micro-organism in a two stage fermentation process where, in a last stage that precedes the end of fermentation, the carbon source is: consumed by the micro-organisms at a rate greater than it is added... Agent: Nixon & Vanderhye, PC

20090047210 - Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.... Agent: Bell, Boyd & Lloyd LLP

20090047209 - Novel nifedipine compositions: The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090047211 - Anti-mesothelin antibodies useful for immunological assays: The present invention provides antibodies that have a surprisingly good combination of affinity for mesothelin and ability to be used in immunological assays for detecting the presence of mesothelin in biological samples. The invention further provides methods of using the antibodies, and kits comprising them. The antibodies can also be... Agent: Townsend And Townsend And Crew, LLP

20090047213 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20090047212 - Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model: The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the... Agent: Edwards Angell Palmer & Dodge LLP

20090047214 - Novel methylation marker: (b) determining the expression levels of a RecQ helicase family gene in a sample obtained from a subject, wherein a reduced level of expression of the RecQ helicase family gene indicates the likelihood of successful treatment is higher than if the RecQ helicase family gene is expressed at a higher... Agent: Foley And Lardner LLP Suite 500

20090047215 - Mn/ca ix and breast cancer therapy: Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to... Agent: Leona L. Lauder

20090047216 - Tumor vasculature markers and methods of use thereof: This invention provides methods of detecting and localizing tumor vasculature cells (TVC) and solid tumors; and treating, impeding vascularization of, and determining the stage of solid tumors in a subject, comprising the step of contacting a subject or a TVC with a ligand that binds to a nucleic acid molecule... Agent: Pearl Cohen Zedek Latzer, LLP

20090047217 - Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby: The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090047220 - Contrast medium for administration to a patient for magnetic resonance imaging: An exemplary contrast medium for administration to a patient for magnetic resonance imaging is shown. The contrast medium includes: a plurality of carbon nanospheres; and an iron containing nano-particle embedded in each of the carbon nanospheres.... Agent: PCe Industry, Inc. Att. Cheng-ju Chiang

20090047218 - Method for producing albumin conjugates comprising an x-ray contrast medium as the active substance: The invention concerns X-ray contrast medium-protein conjugates and in particular X-ray contrast medium-albumin conjugates, medicaments comprising X-ray contrast medium-protein conjugates, processes for the production of such conjugates as well as the use thereof.... Agent: Morris Manning Martin LLP

20090047219 - Visible to near-infrared light probe using energy transfer between luciferase and an organic dye via a sugar chain: An object of the present invention is to produce a luminescent probe that has less biological effects, efficiently emits visible to near-infrared light, which is excellent for the imaging of individuals, and the use thereof. The present invention provides a sugar chain-containing-luciferase derivative, wherein an organic fluorescent dye is bonded... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090047221 - Compounds and compositions useful in the treatment of neoplasia: There is described compounds for use in therapy, said compounds being defined by Formula (1): There is also described an anti-proliferative composition comprising one or more compounds according to Formula (1), and a method of treatment of neoplasia comprising the administration of such a compound or composition.... Agent: Pepper Hamilton LLP

20090047222 - Color stable peroxide containing dentifrice formulations with dye encapsulated silica shell nanoparticles: A composition for minimizing color fading of an oral care composition is provided. The composition comprises: a) an organic dye-encapsulated silica shell nanoparticle matrix, b) a physiologically stable fluoride ion providing compound in an amount of about 0.1% to about 1% by weight, c) a peroxide species providing compound in... Agent: Colgate-palmolive Company

20090047223 - Improvements in or related to organic compoounds: Malodour counteracting preparations for oral use comprising esterified fumarates of the formula (I) wherein X and Y have the same meaning as given in the description, is disclosed. Furthermore, the invention refers to a process for their preparation and to their use for preventing or reducing oral malodour.... Agent: Norris, Mclaughlin & Marcus

20090047227 - Cationic cassia derivatives and applications therefor: This invention relates to cationically derivatized polycalactomannans obtained from cassia tora and cassia obtusifolia and to their use in personal care, household care, and institutional care compositions.... Agent: Legal Department Lubrizol Advanced Materials, Inc

20090047224 - Cosmetic process for preventing or treating the signs of skin ageing or the orange-peel appearance: The present invention relates to the use of at least one compound capable of cleaving the diketone crosslinking bonds between two proteins, in a composition applied topically to the skin, as an agent for preventing or treating the signs of ageing of the skin or the orange-peel appearance. The above... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090047226 - Quick-drying cosmetic emulsions for roll-on application: Cosmetic oil-in-water emulsions that are suitable in particular for application with a roll-on applicator and that exhibit high shelf stability, a non-greasy skin feel, and particularly quick drying characteristics, the emulsions containing a low concentration of oil phase or fat phase as well as at least one polysaccharide.... Agent: Paul & Paul

20090047225 - Storage of pulverulent substances having a high water content: Process to delay the release of water from a pulverulent preparation comprising cosmetic products, cleaning agents and detergents, wherein the pulverulent preparation contains at least 50 wt. % of water and a hydrophobed silicon dioxide powder, wherein the pulverulent preparation is in contact with a hydrophobic material during storage.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090047228 - Assembly for conditioning and applying a nail varnish of high viscosity: A conditioning and application assembly includes a container containing a nail varnish composition comprising a cosmetically acceptable medium and at least one thixotropic thickener, with the composition having a viscosity at 25° C. of at least 0.6 Pa·s. An applicator is provided for taking up the product contained in the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090047229 - Lip gloss: Embodiments of inventive subject matter described herein include a lip gloss comprising: a sugar gel matrix that includes stearoyl inulin and an ester or ether of formula R(1) COOR(2) in which R(1) is a residue of a fatty acid including from 6 to 29 carbon atoms and R(2) is a... Agent: Schwegman, Lundberg & Woessner, P.A.

20090047230 - Phosphorous-containing surfactants as polymeric cationic compound deposition aids: Personal care products exhibiting superior conditioning and/or color fastness can be obtained by use of mixtures of certain phosphate esters and polyquats.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090047231 - Aqueous hair cosmetic composition: Provided is an aqueous hair cosmetic composition containing (A) a tertiary amine type cationic surfactant, (B) an aromatic alcohol, (C) a branched fatty acid or salt thereof, and water, wherein Component (B) and Component (C) at a (B)/(C) weight ratio falls within a range of from 100/1 to 1/10. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090047232 - Formulation and method for treating animal waste: The invention is directed to a formulation and method for treating solid waste from animals. The formulation comprises a surfactant having antimicrobial activity, preferably a cationic surfactant, and a solvent, preferably water. The preferred cationic surfactant is a quaternary ammonium compound. The formulation may further include one or more of... Agent: Edwards Angell Palmer & Dodge LLP

20090047233 - Method for removing phosphate and polymer used therefore: Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional... Agent: Genzyme Corporation Legal Department

20090047234 - Compositions for nasal delivery: The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the... Agent: Nixon & Vanderhye, PC

20090047236 - Mycoattractants and mycopesticides: The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect attractants and/or pathogens. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material. More than one fungus and substrate can be used in combination.... Agent: William R. Hyde

20090047237 - Mycoattractants and mycopesticides: The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect attractants and/or pathogens. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material. More than one fungus and substrate can be used in combination.... Agent: William R. Hyde

20090047235 - Paratransgenesis to control termites or other social insects: A paratransgenesis system is disclosed to kill targeted social insects such as termites and cockroaches, for example the Formosan subterranean termite. A genetically modified yeast can be effectively used to express and deliver lytic peptides directly within the termite gut. Some highly lytic peptides directly damage the insect gut itself,... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20090047240 - Chaperonin 10-induced immunomodulation: The present invention relates to methods for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, methods for treating or preventing a disease or condition in a subject, methods for modulating the production and/or secretion of one or more immunomodulators in a... Agent: Morrison & Foerster LLP

20090047243 - Combinations for the treatment of b-cell proliferative disorders: The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.... Agent: Clark & Elbing LLP

20090047242 - Conditioned blood composition and method for its production: The present invention relates to methods for the production of conditioned blood compositions which comprise induced factors, and to conditioned blood compositions preparable by the method and to the use thereof for the treatment or prevention of a disorder of the human or animal body.... Agent: Ostrolenk Faber Gerb & Soffen

20090047241 - Il-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation: The invention provides compositions and methods for promoting the recovery of bone marrow micro-environment after disease- or treatment-induced damage.... Agent: Hogan & Hartson L.L.P.

20090047244 - Macrocyclic serine protease inhibitors i: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090047238 - Novel spirotropane compounds and methods for the modulation of chemokine receptor activity: o

20090047239 - Stabilised il-21 compositions: Compositions comprising IL-21 and sulphate are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090047245 - Prognostic chronic hepatitis c biomarkers: Methods for identifying biomarkers useful in determining the response of hepatitis C virus (HCV) infected patients hepatitis C specific treatment. In particular, the providing biomarkers that can be used to identify sustained responders and non-responders prior to and/or during hepatitis C specific treatment.... Agent: Mcdermott Will & Emery LLP

20090047246 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection, the methods generally involving administering to an individual in need thereof an effective amount of... Agent: Knobbe Martens Olson & Bear LLP

20090047247 - Pyrrolidine derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090047250 - Methods for treating or preventing neuroinflammation or autoimmune diseases: Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.... Agent: Howard L. Elford

20090047249 - Modulators of toll-like receptor 7: s

20090047248 - Triazolyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090047252 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090047251 - Conjugates of hydroxyalkyl starch and a protein: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.... Agent: Fish & Richardson P.C.

20090047254 - Bacteriophage and their uses: There is provided a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing a bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium. There is also provided a pharmaceutical composition comprising such a bacteriophage.... Agent: Nixon & Vanderhye, PC

20090047253 - Probiotic system for aquaculture: Probiotic bacterial strains are provided which inhibit or prevent growth or pathogenic bacteria in marine organisms. Also provided are methods of culturing marine organisms using the probiotic bacteria.... Agent: Davis Wright Tremaine, LLP/seattle

20090047262 - Expression of class ii transactivator fusion proteins for control of tumor growth: The present invention relates to tumor immunotherapy. In particular, the present invention provides methods and compositions for converting cancer cells into antigen presenting cells. Thus the present invention provides immunogenic compositions for the treatment and prevention of cancer.... Agent: Morrison & Foerster LLP

20090047263 - Nuclear reprogramming factor and induced pluripotent stem cells: The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including... Agent: Greenblum & Bernstein, P.L.C

20090047264 - Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy: The present invention provides an antiallergic agent containing, as an active ingredient, lactic acid bacteria selected from the group consisting of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus fermentum, and combinations thereof. The antiallergic agent is capable of improving allergic diathesis by reducing the IgE level, which is... Agent: Darby & Darby P.C.

20090047255 - Alphavirus and alphavirus replicon particle formulations and methods: Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by said methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations.... Agent: Greenlee Winner And Sullivan P C

20090047256 - Biodegradable elastomers: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the... Agent: Choate, Hall & Stewart LLP

20090047261 - Composition for treatment of articular cartilage damage: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem... Agent: Sughrue Mion, PLLC

20090047258 - Compositions and methods for reversing age-related changes in extracellular matrix proteins: The invention is directed to compositions and methods for reversing age-related changes in extracellular matrix proteins, particularly the collagen framework of basement membranes of various organs. The invention has particular application to age-related changes that impair Retinal Pigment Epithelium (RPE) cell repopulation of human Bruch's membrane.... Agent: Wilmerhale/columbia University

20090047260 - Keratin biomaterials for cell culture and methods of use: Provided herein are cell culture substrates and microcarriers that include a keratin, e.g., in porous particulate form. The substrate may be provided in or further includes a liquid carrier and/or viable cells. The keratin may be alpha kerateines, gamma kerateines, and combinations thereof, and may be in the form of... Agent: Myers Bigel Sibley & Sajovec

20090047259 - Methods of using the calcineurin a variant cna-beta 1: The present invention relates to an inhibitor or activator of the calcineurin subunit Aβ1 isoform (CnAβ1) and the production of a medicament for the treatment of skeletal muscle injury or degeneration or cancer in a subject. CnAβ1 is constitutively active, cyclosporin-insensitive, highly expressed in proliferating myoblasts and human tumors, where... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090047257 - Novel cell populations and uses thereof: The invention provides, among other things, novel cell populations of CD133− cells. Some aspects of the invention provide endothelial generating cells (EGCs), such as, for example, CD34−CD133−CD73−CD14+CD11b+CXCR4+ cells. The invention further provides related compositions, kits and methods of isolating the novel EGC cell populations. Also provided by the invention are... Agent: Ropes & Gray LLP

20090047265 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as... Agent: Jones Day

20090047266 - Lipases for pharmaceutical use: The pharmaceutical use of lipases related to a variant of the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 1, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis,... Agent: Novozymes North America, Inc.

20090047267 - Process for the preparation of a non-corrosive base solution and methods of using same: The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or... Agent: Jeffrey J. King, Esq. Black Lowe & Graham PLLC

20090047268 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof: The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as... Agent: Jones Day

20090047269 - Metabolomic cancer targets: The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer and methods of inhibiting the growth of a cell by altering the level of such metabolites.... Agent: Casimir Jones, S.c.

20090047270 - Enzymatic anticancer therapy: What is provided is a method of treating a patient having a tumor comprising administering an effective amount of adenosine deaminase, preferably polyalkylene oxide conjugated, to a patient in need thereof.... Agent: Lucas & Mercanti, LLP

20090047271 - Stable recombinant adenosine deaminase: A mutein recombinant adenosine deaminase having any oxidizable cysteine residue replaced by a non-oxidizable amino acid residue is disclosed. Stabilized recombinant adenosine deaminase, polymer conjugates and methods of treatment using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090047272 - Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases: Antiviral compositions comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compositions.... Agent: Nutter Mcclennen & Fish LLP

20090047273 - Method for production of recombinant human thrombin ['644]: The present invention relates to a method is provided for producing recombinant human thrombin from recombinant prothrombin using recombinant ecarin having the sequence SEQ ID NO 2 or a homologue thereof.... Agent: Fish & Richardson P.C.

20090047274 - Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases: The present invention discloses a dysregulation of the CDC2L6 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease.... Agent: Venable LLP

20090047276 - Methods for increasing cell or tissue regeneration in a vertebrate subject: A method is provided for increasing the activity of adult and embryonic stem cells, progenitor cells and/or differentiated cells in vivo in a vertebrate subject. Methods are provided for increasing cell or tissue regeneration in a vertebrate subject by administering one or more Wnt/β-catenin signal-promoting agents and/or one or more... Agent: Nixon Peabody LLP - Patent Group

20090047275 - Nell-1 enhanced bone mineralization: The present invention provides Nell-1 genes and gene products and pharmaceutical compositions comprising the same that promote bone mineralization and osteoblast differentiation. The Nell-1 genes and gene products also represent targets for screening for modulators of bone mineralization and osteoblast differentiation. In addition, Nell-1-associated compounds and compositions can be used... Agent: Squire, Sanders & Dempsey L.L.P.

20090047279 - (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs: Novel (R)—N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the (R)—N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, opioid-induced constipation.... Agent: Kelley Drye & Warren LLP

20090047280 - Antibody inhibiting infection of papillomavirus: The present invention relates generally to an antibody that binds specifically to a neutralization epitope at the surface of papillomavirus (residues 36-49 of the minor capsid L2) that does not interfere with virus entry into endosomes and lysosomes. This antibody neutralizes infection of the virus in a dose dependent manner.... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20090047278 - Novel combinational use of sulfonamide compound: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.... Agent: Birch Stewart Kolasch & Birch

20090047277 - Recombinant il-9 antibodies and uses thereof: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune... Agent: Medimmune, LLC Jonathan Klein-evans

20090047281 - Activin-actrii antagonists and uses for increasing red blood cell levels: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Ropes & Gray LLP

20090047282 - Prophylactic/therapeutic agent for cancer: The present invention provides a prophylactic/therapeutic agent for cancer or the like, an agent for promoting apoptosis of cancer cells, an agent for suppressing proliferation of cancer cells, and the like, which comprises a compound or its salt that inhibits an activity of a protein comprising the same or substantially... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090047285 - Compositions and methods for diagnosing and treating cancer: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090047283 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20090047286 - H2n3 influenza a viruses and methods of use: The present invention provides influenza A viruses that include a hemagglutinin subtype H2, a neuraminidase subtype N3, or the combination thereof. Included in the present invention are H2 hemagglutinins and N3 neuraminidases, and the polynucleotides encoding the polypeptides. Antibody to the polypeptides, and methods of using the viruses, polypeptides, polynucleotides,... Agent: Mueting, Raasch & Gebhardt, P.A.

20090047284 - Methods and compositions for pdgf-c activation and inhibition: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of... Agent: Crowell & Moring LLP Intellectual Property Group

20090047287 - Modulation of bone formation: This invention relates to modulating Ror activity (e.g., Ror2 protein activity) and/or 14-3-3 β to affect bone formation or resorption. The invention further relates to compositions and methods for the screening, diagnosis and development of therapies for bone-related disorders such as osteoporosis and bone fracture. Antibodies and antibody fragments directed... Agent: Wyeth Patent Law Group

20090047288 - Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity: A 25 kD β-glucan composition is described herein that effects the CR3-dependent priming of neutrophils and can promote neutrophil killing of iC3b-opsonized targets. Also described herein are methods of enhancing neutrophil cytotoxicity locally at the site of the tumor.... Agent: Biopolymer Engineering, Inc. Dba Biothera, Inc.

20090047289 - Osteopontin specific antibodies and methods of use thereof: Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.... Agent: Dann, Dorfman, Herrell & Skillman

20090047290 - Monoclonal antibodies against beta3 integrins: Monoclonal antibodies prepared against platelet β3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using β3 integrin deficient (β3−/−) mice immunized against platelets or β3 integrin fragments.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090047292 - Graft rejection suppressors: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction... Agent: Fish & Richardson PC

20090047291 - Modulators of hepatocyte growth factor activator: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.... Agent: Genentech, Inc.

20090047293 - Compositions comprising yersinia pestis antigens: Disclosed are several Y. pestis antigens that are particularly suitable for immunisation purposes, particularly when used in combinations.... Agent: Novartis Vaccines And Diagnostics Inc.

20090047294 - Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration: The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a... Agent: Trask Britt

20090047295 - Methods and compositions for reducing stemness in oncogenesis: The invention provides methods and compositions for reducing the number of cancer stem cells in a mixed population of differentiated cells (for example, cancer cells) and cancer stem cells. The cancer stem cells, if present, can be more resistant to traditional drug-based therapies and can provide a source for new,... Agent: Goodwin Procter LLP Patent Administrator

20090047296 - Monomethylvaline compounds capable of conjugation to ligands: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.... Agent: Townsend And Townsend And Crew LLP

20090047298 - Immune system stimulant and process of manufacturing the same: An immune system stimulant for stimulating the production of antibodies against a pathogen comprises said pathogen attenuated by exposure to hydroxyl radicals. The invention also provides a process for the manufacture of an immune system stimulant.... Agent: Macmillan Sobanski & Todd, LLC

20090047297 - Microfluid system for the isolation of bilogical particles using immunomagnetic separation: The present invention relates to a device and to a method for the isolation of biological particles. This device has a throughflow channel 5 and also a first and second magnetic field and also two inlet channels 1, 2 and two outlet channels 3, 4. The first magnetic field is... Agent: Barnes & Thornburg LLP

20090047299 - Modified alpha-galactosyl ceramides for staining and stimulating natural killer t cells: Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.... Agent: Michael Best & Friedrich LLP

20090047300 - Blood-brain barrier epitopes and uses thereof: The invention features a method of identifying an agent and generating an antibody that can cross the blood bram barrier, through the use of novel antigen isoforms of transmembrane domain protein 30A (TMEM30A) This is useful in establishing mechanisms of transmigration across the blood-bram barrier. These antigens are enriched in... Agent: Ade & Company Inc.

20090047302 - Chimaeric human papillomavirus 16 l1 virus like particles and a method for preparing the particles: A method for producing a chimaeric human papillomavirus (HPV) L1 polypeptide containing a heterologous peptide, and in particular, a HPV L2 peptide comprising the steps of introducing a DNA sequence coding for the heterologous peptide into a DNA sequence coding for the L1 polypeptide; introducing the DNA sequence including the... Agent: Serle I Mosoff

20090047301 - Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide... Agent: Knobbe, Martens, Olson & Bear, LLP

20090047303 - Method for improving the immunogenicity of plasmodium antigens: The present invention provides a Malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of Plasmodium antigen polypeptides. Each of the antigen polypeptides is a wild-type antigen protein of Plasmodium or a derivative of the wild-type antigen protein, and each of the antigen polypeptides may be the same,... Agent: Merck And Co., Inc

20090047304 - Composition for body fat reduction: The composition for body fat reduction comprises (A) astaxanthin and (B) at least one of active ingredient, an adsorbent and a solubilizer, a composition comprises (A) Haetmatococcusalga extract containing astaxanthin and (B) at least one of active ingredient, an adsorbent and a solubilizer, and a medicine and food, each containing... Agent: Flynn Thiel Boutell & Tanis, P.C.

20090047305 - Method of producing proanthocyanidin oligomer: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded, and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with... Agent: Dennis G. Lapointe Lapointe Law Group, Pl

20090047306 - Adjuvant compositions: An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and/or MF59), a type 1 adjuvant and/or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s);... Agent: Heslin Rothenberg Farley & Mesiti PC

20090047307 - Chemo-immunotherapy method: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.... Agent: Marshall, Gerstein & Borun LLP

20090047311 - Antibacterial agent composed of silver-containing aluminum sulfate hydroxide particles and use thereof: m

20090047309 - Cosmetic methods and compositions for repairing human skin: The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least... Agent: Mimi Yang

20090047308 - Gradient copolymer, composition including same and cosmetic make-up or care method: Novel gradient copolymers including at least two different and specifically selected monomers, and cosmetic or skin-care compositions including same. The invention also relates to a cosmetic method for make-up or the care of keratin materials, in particular the skin of the body or of the face, the nails, the hair... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090047314 - Microencapsulation systems and applications of same: The invention relates to microencapsulation systems which are characterised in that they are developed from oily substances or sugars and in that they form an essentially organised assembly corresponding to stacks of crystalline structures. The inventive systems can be used for the microencapsulation of one or more substances which are... Agent: Nixon & Vanderhye, PC

20090047312 - Microgel and external compositions containing the same: The present invention provides a microgel having a mean particle size of 0.1-1,000 μm, the microgel being produced from a gel which is formed by use of a hydrophilic compound capable of forming a gel. An external composition containing the microgel provides an excellent sensation during use; i.e., the composition... Agent: Townsend & Banta C/o Portfolio Ip

20090047315 - Porous magnesia and process for preparing the same: The present invention relates to porous magnesia of substantially spherical shape having a silica layer, which may be used as a carrier for deodorants, antibacterials, catalysts, slow action agents (the adsorbent having the possibility of decreasing the effect of the co-administered medicines or fertilizer and plastic additives, and body pigments.... Agent: Millen, White, Zelano & Branigan, P.C.

20090047316 - Porous particles loaded with cosmetically or pharmaceutically active compounds: Individualized porous particles have a volume-average diameter of less than or equal to 10 μm and a specific surface area of greater than or equal to 1 m2/g, and include at least one cosmetically or pharmaceutically active compound present at least inside the particles.... Agent: Oliff & Berridge, PLC

20090047313 - Preparation having skin-moisturizing properties: A permanently skin-moisturizing cosmetic preparation and use thereof.... Agent: Bachman & Lapointe, P.C.

20090047310 - Use of a griffonia extract, in particular griffonia simplicifolia, in a cosmetic or dermatological composition for mitigating pigmentation of skin and skin appendages: This cosmetic or dermatological preparation may also contain any of the following products: at least one other active depigmenting product, at least one substance for filtering or blocking B and/or A ultraviolet radiation, at least one anti-inflammatory product, at least one agent encouraging flaking. It contains from 0.05 to 20%... Agent: Jacobson Holman PLLC

20090047317 - Disinfectant delivery system and method of providing alcohol-free disinfection: A disinfectant delivery system and method of providing alcohol-free disinfection to a body to be disinfected, as well as a method of infection reduction by preparation of a patient before an invasive procedure. A blended cloth comprising first fibers and second fibers is provided with the first fibers generally being... Agent: Barnes & Thornburg LLP

20090047318 - Nanoparticle-coated medical devices and formulations for treating vascular disease: Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20090047321 - Antimicrobial compounds having protective or therapeutic leaving groups: Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving... Agent: Campbell Nelson Whipps, LLC

20090047320 - Apparatus and method for reducing the occurrence of post-surgical adhesions: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in... Agent: Nikolai & Mersereau, P.A.

20090047322 - Degradable hydrophilic block copolymers with improved biocompatibility for soft tissue regeneration: The present application discloses biodegradable polymers, to porous and other materials comprising such polymers, and to various medical uses of such materials, including use as a scaffold for supporting cell adhesion or the in-growth for regeneration of tissue. The polymer is of the formula A—O—(CHR1CHR2O)n-B wherein A is a poly(lactide-co-glycolide)... Agent: Jacobson Holman PLLC

20090047323 - Medical devices containing rapamycin analogs: A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such... Agent: Squire, Sanders & Dempsey LLP

20090047324 - Medical devices containing rapamycin analogs: A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such... Agent: Squire, Sanders & Dempsey LLP

20090047319 - Pharmaceutical composition for obstructive vascular disease: Provided is the excellent prevention or treatment of a vascular occlusive disease such as vascular restenosis. A pharmaceutical composition for a obstructive vascular disease comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference and a collagen molecule. The use of the nucleic... Agent: Oliff & Berridge, PLC

20090047325 - Xenotransplant for cns therapy: Disclosed are compositions and methods for the xenotransplantation treatment of neurological diseases of the central nervous system of a mammal.... Agent: Haynes And Boone, LLPIPSection

20090047326 - Sinus delivery of sustained release therapeutics: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a... Agent: Morrison & Foerster LLP

20090047327 - Sinus delivery of sustained release therapeutics: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a... Agent: Morrison & Foerster LLP

20090047328 - Caffeine delivery systems: Described are caffeine-based delivery vehicles. A first delivery vehicle is a malleable strip that dissolves in an oral cavity. Buccal absorption provides a prompt mental and physical stimulation for the user. The strips are formulated with beneficial ingredients comprising caffeine, taurine and/or nitric oxide. The strips are contained in a... Agent: Greenberg Traurig

20090047329 - Mesocellular oxide foams as hemostatic compositions and methods of use: The present invention relates to hemostatic compositions comprising a mesocellular oxide foam and, optionally, a biologically active agent such as a procoagulant, as well as devices and methods of use to promote blood clotting.... Agent: Bozicevic, Field & Francis LLP

20090047330 - Oral fast dissolving films for erectile dysfunction bioactive agents: A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending... Agent: Ramesh Bangalore

20090047332 - Methods for producing silver-bonded antimicrobial moist wound dressings and moist wound dressings produced by the methods: A method for producing a silver-bonded antimicrobial moist wound dressing. A silver-containing compound is added to a 0.1-30% aqueous solution of an alkaline solvent to dissociate silver ions from the silver-containing compound, dissolving CMC in water or an organic solvent to obtain a CMC solution, the silver ion-containing solution is... Agent: Mcdermott Will & Emery LLP

20090047331 - Sustained release film formulation for healing wound comprising epidermal growth factor: The present invention relates to a sustained release film formulation for healing wound comprising epidermal growth factor, chitosan, viscosity modifiers, plasticizers, and stabilizers. Specifically, the present invention relates to a sustained release film formulation for healing wound comprising epidermal growth factor as an effective ingredient and chitosan as a main... Agent: Birch Stewart Kolasch & Birch

20090047333 - Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail: The present invention aims at providing a pressure-sensitive adhesive composition applicable to nail, which shows superior adhesive performance (adhesive force, cohesion etc.), and superior drug releasability and drug stability, and an adhesive agent for nail, which uses this composition. The composition of the present invention contains a condensation polymer of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090047334 - Transdermal patch for extended delivery of calcium: The present invention relates to a method for delivery of calcium that avoids the problems with orally given calcium tablets. Particularly, the present invention is a transdermal patch for providing between 40 mg and 500 mg of bioavailable calcium to a patient.... Agent: Passe' Intellectual Property, LLC

20090047336 - novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation: A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0... Agent: Leydig Voit & Mayer, Ltd

20090047335 - Anti-angiogenic peptides and methods of use thereof: Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090047340 - Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis: The invention enables management of mammalian disease related to decreased energy production in the mitochondria, the powerhouse of the cell. The invention uses the combination of liposomal reduced glutathione and l-arginine to increase the ability weight loss in individuals with excess weight. The mechanism of weight loss appears to be... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20090047337 - Method of administering a cationic liposomal preparation: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.... Agent: Morgan Lewis & Bockius LLP

20090047338 - Method to treat flavivirus infection with sirna: The present invention is directed to methods of treating flavivirus mediated diseases using siRNAs. The invention is based upon our findings in a mouse model that siRNAs directed against sequences conserved among multiple flaviviruses prevents and treats flavivirus infections. Accordingly, the present invention provides an isolated siRNA comprising a sense... Agent: David S. Resnick

20090047339 - Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof: The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.... Agent: Novartis Vaccines And Diagnostics Inc.

20090047341 - Capsules of core/shell type and preparation process: The present invention relates to a process for the preparation of a suspension of capsules of core/shell type comprising the steps of mixing, at ambient temperature, an oily phase and polymers, at least one of which is an oligomer having a weight-average molecular weight of less than 10 000 and... Agent: Oliff & Berridge, PLC

20090047342 - Methods of treating infectious diseases: The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C8-C16-alpha, beta-unsaturated aliphatic aldehyde, such as trans-2-dodecenal, to the human or other mammal. The parasitic microorganisms may include trypanosomes, bacteria, fungi and... Agent: Gwen R. Acker Wood, Ph.d., J.d. Eckert Seamans Cherin & Mellott, LLC

20090047344 - Formulations: The present invention relates to pharmaceutical compositions for oral administration of active compounds.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090047343 - Method for stabilizing phenylephrine: The present invention relates to a process for stabilizing phenylephrine including drying an acidic solution of phenylephrine and pharmaceutical compositions including stabilized phenylephrine.... Agent: Philip S. Johnson Johnson & Johnson

20090047346 - Sustained release formulations of sotalol: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In... Agent: K & L Gates LLP

20090047345 - Sustained-release tramadol formulations with 24-hour efficacy: A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration... Agent: Paul Marcoux C/o Labopharm Inc.

20090047347 - Compositions for drug administration: The present invention provides compositions and methods and for speeding the onset of drug action and reducing the first-pass effect drug metabolism in fast-dispersing drug formulations.... Agent: Dla Piper LLP (us)

20090047349 - Drug delivery device: Drug delivery devices are provided herein including crosslinked polymeric compositions. The devices may, in embodiments, possess at least two drug release profiles, in embodiments at least three drug release profiles.... Agent: Tyco Healthcare Group Lp

20090047350 - Perforated water soluble polymer based edible films: A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending... Agent: Ramesh Bangalore

20090047348 - Poly(organophosphazene) hydrogels for drug delivery, preparation method thereof and use thereof: A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances are provided.... Agent: LexyoumeIPGroup, LLC

20090047354 - process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate: The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I)... Agent: Dr. Reddy''s Laboratories, Inc.

20090047353 - Changing th1/th2 balance in split influenza vaccines with adjuvants: The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e.g., it is free... Agent: Novartis Vaccines And Diagnostics Inc.

20090047352 - Colourant compositions and their use: A fibre colourant and an ink composition are provided which comprise monodisperse particles capable of forming a colloidal crystal that diffracts light having a wavelength in a range that corresponds to the wavelength of visible light. The use of such compositions in colouring substrates is also provided.... Agent: Unilever Patent Group

20090047355 - Process for producing pulverulent phytosterol formulations: A process for the production of pulverulent phytosterol formulations, includes preparing an aqueous solution, suspension or dispersion of the phytosterol in an aqueous molecular dispersion or colloidal dispersion of a protective colloid and drying.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090047351 - Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom: A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090047356 - Tissue factor compositions and methods: Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include... Agent: Greenlee Winner And Sullivan P C

20090047357 - Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol: Drug-containing wax matrix granules having at least one wax and at least one drug are produced by the following steps (i) and (ii): (i) supplying the at least one drug and the at least one wax to an extruder in which the temperature of a barrel and the temperature of... Agent: Sughrue Mion, PLLC

20090047358 - Phospholipid-based powders for drug delivery: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.... Agent: Nektar Therapeutics

20090047359 - Ointment for combating and treating skin diseases, and process for preparing said ointment: It also describes a process for preparing said ointment basically consisting of preparing a completely homogenized composition from the mentioned ingredients with the use of a stirring device for a time of about 30 minutes and maintaining the temperature at around 20° C. in order to obtain the cream or... Agent: Hughes Hubbard & Reed LLP

20090047360 - Bone morphogenic protein binding peptide: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces... Agent: Mcdermott, Will & Emery LLP Attn:IPDepartment

20090047361 - Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health: This invention is directed to compositions for animal consumption (including foods, treats, etc.), particularly compositions that tend to improve kidney function, and particularly compositions that comprise enhanced antioxidants and reduced quantities of protein and/or phosphorus. This invention also is directed generally to methods for using such compositions.... Agent: Colgate-palmolive Company

20090047362 - Method for in-vitro stabilization of heavy metals: This invention provides a method for reducing the level of 1.0 Normal HCL soluble heavy metals within the human stomach acid environment by oral ingestion of stabilizing agents such that the heavy metal solubility is reduced and subsequent heavy metal transfer to the blood stream is reduced to acceptable levels... Agent: Keith E. Forrester

20090047363 - Deodorant antibacterial fibrous product: A deodorant antimicrobial fibrous product containing a cancrinite-like mineral containing an antimicrobial metal, a clay mineral, softwood bleached kraft pulp, and hardwood bleached kraft pulp. The weight ratio of the softwood bleached kraft pulp to hardwood bleached kraft pulp is preferably 95/5 to 50/50. The clay mineral is preferably zeolite,... Agent: Birch Stewart Kolasch & Birch

20090047364 - Disinfecting methods and compositions: A method of disinfecting surfaces said method comprising applying a disinfectant solution to surface to be disinfected and allowing the solvent to evaporate or wiping the excess solution from the surface after a period of time wherein the solution is an antimicrobial metal ion-acid solution.... Agent: Edward K. Welch Ii Ip&l Solution

20090047365 - Novel concomitant use of sulfonamide compound with anti-cancer agent: The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.... Agent: Birch Stewart Kolasch & Birch

20090047366 - Inorganic coagulation accelerators for individuals taking platelet blockers or anticoagulants: The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials to the wound of a patient on anticoagulant or platelet blocker therapy. The method comprises contacting such wounds with a substance selected from the group consisting of zeolitic molecular sieves and non-zeolitic... Agent: Honeywell International Inc Patent Services

20090047367 - Pharmaceutical composition for improving anxious behaviors of animals and method for preparing the same: A pharmaceutical composition is disclosed in the present invention, which contains a medical material of Triticum aestivum L., a medical material of Glycyrrhizae Radix, and at least one calcium ion source. The pharmaceutical composition of the present invention can be taken by animals so as to improve anxious behaviors of... Agent: Bacon & Thomas, PLLC

20090047368 - Polymeric polyphenol extracted from fermented tea, therapeutic agent for mitochondrial disease, preventive/therapeutic agent for diabetes mellitus, and food or beverage: [Solution] To provide high-molecular-weight polyphenols extracted from fermented tea (e.g. oolong tea or black tea), which are high-molecular-weight polyphenols with a number average molecular weight ranging from 9,000 to 18,000, and containing in their partial structures a procyanidin structure of polymerized catechins and/or their gallates, and a structure of linkage... Agent: Jordan And Hamburg LLP

20090047369 - Composition comprising 4-carbon dicarboxlic acids for improvement of memory function: Disclosed herein is a composition for the improvement of memory and learning functions, which contains 4-carbon dicarboxylic acid or a salt thereof and an emulsifying agent. The composition shows a more remarkable effect when it additionally contains a concentrate or alcohol extract of maesil. Because the composition improves learning and... Agent: Staas & Halsey LLP

20090047370 - Topical treatment of peripheral neuropathy: A method and composition for the treatment of diabetic neuropathy is disclosed. A preferred embodiment of the invention relates to a topical composition for the treatment of systems related to diabetic neuropathy by application to the affected area. The composition provides relief of these symptoms and inhibits those factors that... Agent: Baker & Hostetler LLP

20090047371 - Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field: The present invention concerns a pharmaceutical composition containing curcumin and resveratrol and its application in the medical field. In particular, the composition according to the invention can be advantageously employed for preventing ageing and vascular diseases, for the treatment and the prophylaxis of cancers as prostate carcinoma, of skin diseases... Agent: Young & Thompson

20090047372 - Producing a topical solution coposition: The invention relates to revitalizing layers of the skin which have been damaged by sunlight exposure and particularly ultraviolet radiation by applying a topical solution composition that includes a concentrated amount of resveratrol which has been extracted from a red wine.... Agent: Craig Miller

20090041659 - Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making... Agent: Ropes & Gray LLP

20090041660 - Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc): The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease.... Agent: Morgan & Finnegan, L.L.P.

20090041661 - Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products: Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in... Agent: Morrison & Foerster LLP

20090041662 - Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method: t

20090041663 - Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors: Novel benzamide compounds of Formula (I), Formula (II), and Formula (III), salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A method for diagnosing a mammal for the presence of a mammalian tumor therein comprises administering to the... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20090041664 - 5-pyrrolidinylsulfonyl isatin derivatives: The present invention relates to novel 5-pyrrolidinylsulfonyl isatin derivatives, non-peptidyl Caspase binding Radioligands (CbRs) and CbR-transporter conjugates derived from said isatin derivatives, diagnostic compositions comprising said compounds of the invention and their use for non-invasive diagnostic imaging.... Agent: Kagan Binder, PLLC

20090041665 - Method for gene delivery to neuronal cells: The present invention relates to the use of axonal transport to deliver a baculovirus vector to a target neuronal cell by administering the vector to a site that is remote from the target cell. Such delivery allows for tracing of neuronal pathways and further a baculovirus vector may be used... Agent: Klarquist Sparkman, LLP

20090041666 - Ophthalmic formulations of amyloid-beta contrast agent and methods of use thereof: The invention provides ophthalmic formulations of Amyloid-β contrast agents. Also provided are methods of using such formulations in the diagnosis of Alzheimer's Disease or a predisposition thereto as well as methods for the prognosis of Alzheimer's Disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090041667 - Treatment of depressive disorders: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090041674 - Targeted iron oxide nanparticles: Iron oxide nanoparticles comprising functional groups of the formula —X—NH2 on the outer surface of said nanoparticles, wherein X is selected from O, NR, NH or S, where R is C1-7 alkyl and conjugate particles comprising an iron oxide nanoparticle linked via a bond of formula —C═N—X— to a cell... Agent: Bozicevic, Field & Francis LLP

20090041673 - Thermally crosslinked contrast agents: The present invention relates to a contrast agent comprising a plurality of nanoparticles, wherein each of the nanoparticles comprises: (a) a signal generating core; and (b) a polymeric shell coated on the signal generating core, wherein the polymeric shell comprises a water soluble hydoxysilyl- or alkoxysilyl-functionalized polymer and wherein the... Agent: Sughrue Mion, PLLC

20090041671 - Protein cages for the delivery of medical imaging and therapeutic agents: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090041669 - Light-emitting biomarker: The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical or biological, in particular enzymatic, phenomenon, as well as a kit for implementing said method.... Agent: Oliff & Berridge, PLC

20090041670 - Near infrared fluorescent contrast agent and method for fluorescence imaging: A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R7, and R8 represent a C1-C10 alkyl group or the... Agent: Millen, White, Zelano & Branigan, P.C.

20090041668 - Non-invasive localization of a light-emitting conjugate in a mammal: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking... Agent: Robins & Pasternak

20090041672 - Drug for treating or diagnosing vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation: A novel drug for treating a vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation which is efficacious in treating a vascular lesion in the deep part of the skin or the subcutaneous soft tissue caused by light irradiation without destroying normal cells on the... Agent: Birch Stewart Kolasch & Birch

20090041677 - Azeotrope-like compositions of 1-chloro-3,3,3-trifluoropropene and methyl iodide: An azeotropic or azeotrope-like composition comprising a mixture of methyl iodide, 1-chloro-3,3,3,-trifluoropropene, and optionally one or more of fluorocarbons and/or hydrofluorocarbons. The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a... Agent: Honeywell International Inc.

20090041675 - Organic compounds: in free or salt or solvate form, where W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification, and (B) one or more of compounds selected from the group consisting of PDE4 inhibitors and PDE5 inhibitors, for simultaneous, sequential or separate... Agent: Novartis Corporate Intellectual Property

20090041676 - Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough, asthma and tussive attacks: An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline... Agent: Peters Verny , L.L.P.

20090041681 - Anti-inflammatory inhalation pharmaceutical composition:

20090041679 - Human neutralizing monoclonal antibodies to h5n1 influenza a virus: A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090041678 - Metronidazole-based dermatological foams and emulsions for the preparation thereof: p

20090041680 - Wax foamable vehicle and pharmaceutical compositions thereof: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free... Agent: Wilmerhale/boston

20090041682 - Medical product: The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090041683 - Hair styling composition: The present invention is related to a hair styling composition for keratin fibres especially for hair comprising at least one film forming polymer and at least one arylated silicone.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041684 - Formulation for prophylaxis of oral cavity diseases: The invention relates to medicine, namely, to stomatology, in particular, to formulation for prophylaxis of oral cavity diseases. The formulation comprises: drinking water, glycerol, xylitol, silica, xanthan gum, methylparaben, propylparaben, titanium dioxide, perfume, bromelain, sodium saccharin, sodium lauryl sulfate or alkylamidobetain, calcium glycerophosphate, and magnesium chloride or glycerophosphate magnesium at... Agent: Mikhail Utkin

20090041690 - Autobronzing composition: The present invention pertains to an auto-bronzing composition including (i) at least one auto-bronzing agent, (ii) at least one auto-bronzing reactive material (“ARM”) chosen from the group consisting of amphiphilic copolymers of AMPS with at least one hydrophobic comonomer and (iii) at least one specific emulsifier. The emulsifier (iii) is... Agent: Young & Thompson

20090041685 - Cosmetic delivery system and process for manufacture thereof: A benefit agent delivery system for use in cosmetic or cleansing products is provided comprising a polysaccharide-zein complex, a benefit agent and a plasticiser. The delivery system enhances the stability of the benefit agent whilst providing for shear-triggered release of the benefit agent on application of a product to a... Agent: Unilever Patent Group

20090041689 - Polyurethane dispersions based on polycarbonate polyols and suitable for use in personal care products: The invention relates to a process for preparing an aqueous polyurethane dispersion suitable for use in personal care products, wherein the polyurethane is based on one or more polycarbonate polyols.... Agent: Bayer Material Science LLC

20090041688 - Sunless tanning compositions comprising certain substituted polyamine compounds and methods of use: The present invention is directed to cosmetic and/or dermatological compositions for enhancing the rate of tanning human skin with sunless tanning compositions and providing the added benefit of simultaneously providing protection from ultraviolet light radiation. More particularly, the present invention is directed to a sunless tanning composition comprising a sunless... Agent: Joann Villamizar Ciba Corporation/patent Department

20090041686 - Topical acne vulgaris composition with a sunscreen: Increased compliance in the use of topical sunscreens is obtained by combining a topical sunscreen agent in a formulation containing an antibacterial medication such as azelaic acid or an antibiotic.... Agent: Howard Eisenberg, Esq.

20090041687 - Use of opioid receptor antagonists: The present invention relates to a new use of opioid receptor antagonists. More particularly, the present invention relates to the use of opioid receptor antagonists for the manufacture of topical compositions for suppression of melanin formation in the human skin; to topical, particularly cosmetic, compositions for suppression of melanin formation... Agent: Nixon & Vanderhye, PC

20090041691 - Sun protection compositions comprising semi-crystalline polymers and hollow latex particles: e

20090041693 - Bleaching/highlingting composition: The present invention relates to water free bleaching composition in form of a dust free powder or a suspension, which comprises at least one arylated silicone at a concentration of 1 to 50% by weight calculated to total composition.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041692 - Methods of producing lignin peroxidase and its use in skin and hair lightening: Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening.... Agent: Martin D. Moynihan Prtsi, Inc.

20090041695 - Compositions for making up keratinous materials: t

20090041696 - Compositions for making up keratinous materials: monodisperse particles each comprising a core that is insoluble in the medium, with polymer chains that are soluble in the medium extending from the surface of the cores, in particular by grafting, the monodisperse particles being suitable for forming an ordered lattice of monodisperse particles onto a surface to which... Agent: Oliff & Berridge, PLC

20090041694 - Preparation, in particular cosmetic preparation, production and use thereof: A preparation comprising at least one silicone, at least one PEG/PPG dimethicone with 15 to 20 units of PEG and PPG respectively as an emulsifier, a lipid phase, water in a proportion of 0.1 to 5% with respect to the total weight of the composition and at least one particulate... Agent: Bachman & Lapointe, P.C.

20090041697 - Film-forming compositions for protecting skin from body fluids and articles made therefrom: A film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition includes a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may include a skin care ingredients for treating or maintaining skin health. The composition... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090041698 - Cosmetic product in the form of compact powder comprising a message informing the user: A compressed powder product (60) intended for cosmetic use comprises at least one string of alphanumeric characters (24) displayed essentially throughout said usable thickness h and forming a message that is intended to inform the user of said product about at least one commercial, technical or regulatory characteristic of said... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090041699 - Two-phase composition for conditioning hair: c

20090041708 - Conditioning composition for hair comprising optical brightener: The present invention is related to a conditioning composition for hair comprising optical brightener and ubichinone. The conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041710 - Conditioning composition for hair: The present invention is related to a conditioning composition for hair comprising at least one polyphenol and at least one arylated silicone selected from phenyl methicone, phenyl trimethicone, diphenyl dimethicone, diphenylsiloxy phenyl trimethicone, tetramethyl tetraphenyl trisiloxane, triphenyl trimethicone, teramethly tetraphenyl trisiloxane and pentaphenyl trimethly trisiloxane. The conditioning composition of the... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041709 - Conditioning composition for keratin fibres: The present invention relates to a conditioning composition for keratin fibres especially human hair comprising particular cationic polymers and a cationic silicone compound. The present inventor has surprisingly found out that an aqueous hair conditioning composition comprising at least two cationic polymers, one being a cationic polymer with multiple cationic... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041711 - Conditioning composition for keratin fibres: The present invention relates to a conditioning composition for keratin fibres especially human hair comprising particular cationic cellulose polymer and a cationic or cationizable silicone compound.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041712 - Water-in-silicone emulsion compositions: The present invention relates to a composition containing a retinoid and/or peptide complexed with a copper ion wherein the composition is a water-in-silicone emulsion, and the use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20090041700 - Composition for permanent shaping human hair: e

20090041701 - Hair care composition:

20090041713 - Hair care composition:

20090041705 - Composition for keratin fibres: The present invention relates to a conditioning and shine enhancing composition for keratin fibres especially human hair. Accordingly the subject of the present invention is an aqueous composition comprising at least one mono alkyl quaternary ammonium surfactant at a concentration of 0.01 to 10% by weight, and at least one... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041702 - Conditioning composition for hair: The present invention is related to a conditioning composition for hair based on polyphenols, Ubichinone and UV filters. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041706 - Conditioning composition for hair: The present invention is related to a conditioning composition for hair comprising at least one polyphenol and at least one silicone quaternary compound. The conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041707 - Conditioning composition for hair: The present invention is related to a conditioning composition for hair comprising at least one arylated silicone and at least one silicone quaternary compound. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after... Agent: Norris, Mclaughlin & Marcus, P.A.

20090041704 - Multi-phase composition for conditioning hair: e

20090041703 - Two or multi-phase composition for conditioning hair:

20090041714 - Polymer-factor viii moiety conjugates: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent: Nektar Therapeutics

20090041716 - Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt: The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1 H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline... Agent: Louis J. Wille Bristol-myers Squibb Company

20090041715 - Epothilone combinations: The invention relates to combinations of (a) an epothilone with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease.... Agent: Novartis Corporate Intellectual Property

20090041717 - High affinity human antibodies to human nerve growth factor: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or... Agent: Regeneron Pharmaceuticals, Inc

20090041718 - Methods of modulating cytokine activity; related reagents: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.... Agent: Dnax Research Inc. Legal Department

20090041720 - Heteroaryl substituted thiazoles: and pharmaceutically acceptable salts thereof. The variables A and R3 to R7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds,... Agent: Cantor Colburn, LLP

20090041719 - Method for screening therapeutic agent for glomerular disorder: The present invention relates to a method for screening a compound for preventing, ameliorating or treating glomerular lesions or disease of kidney, characterized by assaying the regulating activity of compound on 4F2hc expression shown by contacting human peripheral blood mononuclear cells or monocytes or an established line of human cultured... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090041721 - Arylalkoxyl hepatitis c virus protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090041722 - Indole indane amide compounds useful as cb2 agonists and method: i

20090041723 - Compounds and methods for treatment of hcv: Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.... Agent: Fenwick & West LLP

20090041724 - Protein delivery system: The present invention relates to a virus-like particle (VLP) having a plasma membrane-derived lipid bilayer envelope, said VLP further comprising a viral structural protein, or fragment or derivative thereof, capable of forming an enveloped VLP, a fusiogenic protein and a recombinant target protein; methods for the delivery of recombinant target... Agent: Crowell & Moring LLP Intellectual Property Group

20090041725 - Replication-deficient rna viruses as vaccines: The present invention relates to a genome-replication-deficient and transcription-competent negative-strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development.... Agent: Beusse Wolter Sanks Mora & Maire

20090041726 - Tumor therapy with high affinity laminin receptor-target vectors and combinations with chemotherapeutic agents: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to... Agent: Darby & Darby P.C.

20090041735 - Cd34 stem cell-related methods and compositions: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34− stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34− stem cells used in the instant methods can be genetically modified or... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090041734 - Use of cell implants in bladder and gut of non-human animals for the production of peptides: Provided are means and method for the production of proteins in non-production in non-human animals. Cells producing a protein of interest is implanted in said non-human animal whereupon produced protein is harvested. In a preferred embodiment cells are implanted into a bladder or gut of said non-human animal... Agent: Trask Britt

20090041727 - Compositions and methods for microbe storage and delivery: The present invention relates to the field of bacteriology. In particular, the invention relates to compositions of probiotic microbes and methods for making and using such compositions, e.g. in the treatment and prevention of catheter associated urinary tract infections.... Agent: Casimir Jones, S.c.

20090041728 - Proteoglycan degrading mutants for the treatment of cns: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.... Agent: Pepper Hamilton LLP

20090041736 - Synbiotic mixture: This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising Ga1NAcα1,3Ga1β1,4G1c and Ga1β1,6Ga1NAcα1,3Ga1β1,4G1c, 20-95 wt % of at least one neutral oligosaccharide selected from the group comprising Ga1β1,6Ga1, Ga1β1,6Ga1β1,4G1c Ga1β1,6Ga1β1,6G1c,... Agent: Bell, Boyd & Lloyd LLP

20090041730 - Joint repair using mesenchymal stem cells: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.... Agent: Mcandrews Held & Malloy, Ltd

20090041733 - Methods for cell mobilization using in vivo treatment with hyaluronan (ha): The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090041729 - Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced: The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a... Agent: Morgan Lewis & Bockius LLP

20090041732 - Survivin peptides as cancer vaccines: Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in... Agent: Hodgson Russ LLP The Guaranty Building

20090041731 - Treatment for diabetes: Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-α, in an amount sufficient to effect differentiation of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090041737 - Cold storage of modified platelets: A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker... Agent: Ogilvy Renault LLP

20090041738 - Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells: The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected... Agent: Richard R. Muccino

20090041739 - Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells: The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected... Agent: Richard R. Muccino

20090041740 - Cancer treatment by metabolic modulations: The invention provides compositions and methods for inhibiting the growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells. More specifically, the invention provides compositions and methods for stimulating glycogen accumulation in target cells (e.g., hyperproliferative cells) in order to increase glycogen to a level that is toxic... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090041741 - Modified enzyme and treatment method: There is disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moeties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity Also disclosed are methods for the treatment of lysosomal storage disease in... Agent: Husch Blackwell Sanders LLP

20090041744 - Dimeric and multimeric fviia compounds: The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090041742 - Human dnase ii: This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and... Agent: Genentech, Inc.

20090041743 - Sperm-blocking agent composition with contraceptive effect: A sperm-blocking agent is disclosed. The composition comprises an aqueous solvent a gum which is a polysaccharide having about 0.3 to 10 wt % of the composition, wherein the polysaccharide is selected from the group consisting of celluloses and their derivatives, hemi-cellulose, fiber, starches and their derivatives, polydextrans and their... Agent: Leong C Lei

20090041746 - Combination therapy with iga1 proteases: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are... Agent: Choate, Hall & Stewart LLP

20090041745 - Modulators of paraptosis and related methods: The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), kainic acid and glutamic acid, wherein the... Agent: Morrison & Foerster LLP

20090041747 - Compounds for stabilizing factor vii polypeptide formulations: The invention relates to novel compounds with formula (I) and their use in stabilization of Factor VIIa or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090041748 - Fibrinogen-based tissue adhesive containing an elastase inhibitor: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.... Agent: Baxter Healthcare Corporation

20090041756 - 121p1f1: a tissue specific protein highly expressed in various cancers: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides... Agent: Agensys C/o Morrison & Foerster LLP

20090041757 - Bone morphogenetic protein antagonist and uses thereof: The present invention relates to the use of proteins that are differentially expressed in tumor associated stromal cells, as compared to normal stromal, as biomolecular targets for tumor treatment therapies. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.... Agent: Bozicevic, Field & Francis LLP

20090041749 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20090041752 - Compositions and methods for the treatment and diagnosis of immune disorders: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within... Agent: Millennium Pharmaceuticals, Inc.

20090041753 - Cytokine signaling: The present invention relates to compositions and methods for targeting CXC-chemokine mediated signaling for treatment of a myelin disorder.... Agent: Wilson Sonsini Goodrich & Rosati

20090041759 - Materials and methods for treating ocular-related disorders: The invention is directed to a method of delivering a gene product to an animal. The method comprises administering an expression vector comprising a nucleic acid sequence operably linked to a promoter and encoding a gene product, and upregulating transcription of the nucleic acid sequence in the ocular cell. The... Agent: Leydig Voit & Mayer, Ltd

20090041754 - Method for identifying target protein of drug and method for screening therapeutic agent for diabetes using the target protein: A method for identifying a target protein of a compound having a pharmacological action by detecting a tertiary structural change of a target protein by binding a compound having a pharmacological action to a target protein with the use of a molecular chaperone protein having a characteristic of binding to... Agent: Sughrue-265550

20090041755 - Methods and compositions for pdgf-d activation and inhibition: Methods for inhibiting angiogenesis comprising administering urokinase plasminogen activator (uPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the uPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering uPA or an agonist thereof to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of... Agent: Crowell & Moring LLP Intellectual Property Group

20090041758 - Modified binding molecules comprising connecting peptides: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090041760 - Retroviral immunotherapy: The present inventor has noted that at least two populations of immune cells are produced in response to retroviruses which infect mammals. More particularly, the immune system of a mammal infected with a retrovirus is capable of mounting an immune response against the virus through a group of cells herein... Agent: Wilmerhale/boston

20090041751 - Sepsis prevention through adenosine receptor modulation: Methods for treating sepsis or septic shock in a patient comprising administering to said patient a therapeutically effective amount of a composition containing an adenosine A2a receptor antagonist.... Agent: Fox Rothschild LLP

20090041750 - Treatment of spongiform encephalopathy by increased hydrogen peroxide degradation: The present invention relates to the treatment of CJD and other spongiform encephalopathies by increasing the level and/or activity of hydrogen peroxide degrading enzymes, such as catalase and glutathione peroxidase, in order to deplete hydrogen peroxide and prevent the build up of gaseous oxygen in the brains of patients. Various... Agent: Nixon & Vanderhye, PC

20090041761 - Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody: It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090041766 - Antibodies for inhibiting blood coagulation and methods of use thereof: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor... Agent: Morrison & Foerster LLP

20090041763 - Composition comprising humanized antibody hbbk4 for the treatment of cancer and the use thereof: The present invention is related to a pharmaceutical composition comprising humanized anti-4-1BB antibody (HBBK4) for treating cancer by inducing increase of CD11+CD8+ T cell and IFN-γ, and inhibiting proliferation of cancer cells, together with a pharmaceutically acceptable carrier and the use. Accordingly, it can be useful in the prevention or... Agent: Kirk Hahn

20090041765 - Materials and methods for improved immunoglycoproteins: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.... Agent: Marshall, Gerstein & Borun LLP (trubion)

20090041764 - Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency: The use of therapeutics capable of inhibiting complement such as an anti-C5 antibody to treat muscular dystrophy associated with dysferlin-deficiency is disclosed.... Agent: Ropes & Gray LLP

20090041762 - Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090041768 - Modified fc molecules: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... Agent: Amgen Inc.

20090041767 - Pharmaceutical combinations: Pharmaceutical combinations comprising an α5β1 antagonist in combination with a tyrosine kinase inhibitor. In some embodiments, the α5β1 antagonist is volociximab. In some embodiments, the tyrosine kinase inhibitor is sunitinib or a pharmaceutically acceptable salt thereof. The invention also relates to methods for treating cancer by administering the pharmaceutical combinations... Agent: Howrey LLP-ca

20090041770 - Fc variants with altered binding to fcrn: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.... Agent: Xencor

20090041769 - Methods of treatment using ctla4 mutant molecules: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33... Agent: Louis J. Wille Bristol-myers Squibb Company

20090041774 - Haemophilus influenzae type iv pili: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and... Agent: Marshall, Gerstein & Borun LLP

20090041771 - Immunological methods and compositions for the treatment of alzheimer's disease: The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta42. The invention further relates to antibodies that bind to the Abeta(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090041773 - Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or... Agent: Alston & Bird LLP

20090041772 - Soluble forms of hendra and nipah virus g glycoprotein: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah... Agent: Morgan Lewis & Bockius LLP

20090041776 - Production of cancer-specific antibodies in plants: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090041775 - Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract: Use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His, said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly, and said CDR3 having... Agent: Novartis Corporate Intellectual Property

20090041777 - Human antibodies against rabies and uses thereof: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090041779 - Aldosterone induced elastin production: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.... Agent: Pepper Hamilton LLP

20090041778 - Methods and compositions for the treatment of graft failure: The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate), or mTOR inhibitors (e.g., rapamycin).... Agent: Clark & Elbing LLP

20090041780 - Concentrate of immunoglobulins and f(ab)'2 and/or fab fragments specific of an arbovirus as a medicinal product: The invention concerns a new medicinal product for the treatment of arboviruses, i.e a concentrate of immunoglobulins and F(ab)′2 and/or Fab fragments specific to said arbovirus as well as its process of preparation.... Agent: Cermak Kenealy & Vaidya LLP

20090041781 - Methods for detecting parvovirus infections: The present invention provides a method for diagnosing a subject suffering a pathological condition characterized by parvovirus infection by detecting the presence of IgE anti-Parvovirus B 19 antibodies.... Agent: Scully Scott Murphy & Presser, PC

20090041782 - Novel serotype streptococcus mutans and utilization of the same: A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of Streptococcus mutans; novel Streptococcus mutans strain having the above polynucleotide; an antibody specific to this Streptococcus mutans strain; and a method of detecting the above-described Streptococcus mutans strain occurring in a subject... Agent: Drinker Biddle & Reath (dc)

20090041783 - Anti-platelet membrane glycoprotein vi monoclonal antibody: p

20090041784 - Compositions and methods relating to glucagon receptor antibodies: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type... Agent: Amgen Inc. Law Department

20090041785 - Use of anti-integrin antibodies for reducing scar tissue formation: The present invention provides methods that enable the user to identify inhibitors of tissue granulation in and around a wound site, thereby limiting excessive scar formation as the wounded tissue heals. The some granulation inhibitors identified using the methods of the invention inhibit granulation in and around a wound site... Agent: Howrey LLP-ca

20090041788 - Apo-2l receptor agonist and cpt-11 synergism: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells, are provided.... Agent: Genentech, Inc.

20090041787 - Chemokine receptor antagonists as therapeutic agents: The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining... Agent: Kilpatrick Stockton LLP

20090041786 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20090041790 - Methods for treating cardiovascular disease using a soluble ctla4 molecule: The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090041789 - Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or... Agent: Cermak Kenealy & Vaidya LLP

20090041791 - Heterocyclic self-immolative linkers and conjugates: The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that... Agent: Heller Ehrman LLP

20090041792 - Dendritic cells, uses therefor, and vaccines and methods comprising the same: Provided is a method of cross-priming CD8+ T cells to antigens using Dendritic Cells cultured in the presence of a type I Interferon and GM-CSF, and vaccines and methods of vaccination comprising said Dendritic Cells.... Agent: Quine Intellectual Property Law Group, P.C.

20090041794 - Identification of hla-a2-presented t-cell epitopes derived from the oncofoetal antigen-immature laminin receptor protein and uses thereof: The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090041793 - Immunostimulatory compositions and uses thereof: The present invention provides novel immuno-stimulatory polypeptides, and methods for their use and identification.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090041795 - Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture: The present invention provides isolated or synthesized peptides of about 7 to about 50 amino acids identified in the genome of pathogens in invertebrates in aquaculture for prevention and treatment of outbreaks of these pathogens in aquaculture and methods of preventing and treating pathogenic outbreaks using the identified peptides.... Agent: Kenyon & Kenyon LLP

20090041797 - Modified toxins: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue... Agent: Wilson Sonsini Goodrich & Rosati

20090041796 - Surface protein of leptospira: The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods.... Agent: Fulbright & Jaworski, LLP

20090041798 - Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise Leishmania sterol 24-c-methyltransferase (SMT) polypeptides, portions, variants and/or fusions, as well as polynucleotides encoding SMT polypeptides, portions, variants and/or fusions.... Agent: Seed Intellectual Property Law Group PLLC

20090041800 - Methods for treating dependence: Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients... Agent: Fenwick & West LLP

20090041799 - Physiologically active substance nk13650p3, method of producing the same and use thereof: A physiologically active substance NK13650P3 having the following physicochemical properties or a pharmacologically acceptable salt thereof. 1) Appearance: pale yellow powder 2) Molecular formula: C29H37N7O15 3) Molecular weight: 723 4) Hydrogen nuclear magnetic resonance spectrum: spectrum measured at 600 MHz in heavy water contains the following signals: chemical shift value... Agent: Nields & Lemack

20090041801 - Metal chelator: A natural substance composition for the elimination of toxic metals from the body comprising a homeopathic detox factor, a nucleotide-peptide complex and coriander sativum.... Agent: Howson And Howson

20090041802 - Immunogenic composition: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090041803 - Dioscorea extracts: An extract from a tuber of a Dioscorea plant is disclosed. Also disclosed is a composition containing an extract from a tuber of a Dioscorea plant, as well as methods of using the extract and composition.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090041804 - Recombinant vector expressing multiple costimulatory molecules and uses thereof: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is... Agent: Leydig, Voit & Mayer, Ltd.

20090041805 - Botulinum toxin for treating postherpetic neuralgia: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.... Agent: Allergan, Inc.

20090041806 - Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity: Methods of treating spasticity by administering a colonically absorbable prodrug of a GABA analog having antispastic activity that is not directly mediated by the GABAB receptor, optionally in combination with an antispasticity agent or a colonically absorbable prodrug of a GABAB receptor agonist are disclosed. In particular, methods of treating... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090041807 - Stable compositions containing omvs: An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.... Agent: Hodgson Russ LLP The Guaranty Building

20090041808 - Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction: The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating... Agent: Venable LLP

20090041809 - Double-stranded locked nucleic acid compositions: Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA.... Agent: Sughrue Mion, PLLC

20090041810 - Immunostimulating polyphosphazene compounds for intradermal immunization: Disclosed are intradermally administered products and methods for producing an immune response in a human or in an animal comprising an antigen and a polyphosphazene polyelectrolyte adjuvant in an amount effective to elicit an immune response in the human or in the animal against said antigen.... Agent: Raymond E. Stauffer C/o Carella, Byrne, Bain, Gilfillan,

20090041811 - Oil-in-water emulsion composition: The present invention is an oil-in-water emulsion composition containing a hydrophilic non-ionic surfactant or hydrophilic anionic surfactant, a higher aliphatic alcohol, water, and an oil ingredient which meets specific conditions. This is an oil-in-water emulsion composition with good high temperature stability and usability, and can be used as a cream-like... Agent: Townsend & Banta C/o Portfolio Ip

20090041813 - Active substance composition comprising at least one nitrogen atom-containing, hyperbranched polymer: Compositions comprising: (a) at least one hyperbranched polymer comprising nitrogen atoms; and (b) at least one substance exhibiting a solubility in water at 25° C. and 1013 mbar of less than 10 g/l are disclosed along with methods of preparing such compositions.... Agent: Connolly Bove Lodge & Hutz, LLP

20090041815 - Assembly comprising a substrate comprising biocellulose, and a powdered cosmetic composition to be brought into contact with the substrate: m

20090041816 - Coated particles: A coated particle is disclosed comprising a core, a first innermost layer coating the core, a second middle layer coating the first innermost layer and a third outermost layer coating the second middle layer, wherein the core comprises at least a water-in-oil emulsion or a fat and/or oil, wherein the... Agent: Unilever Patent Group

20090041814 - Cosmetic composition: The invention provides a cosmetic composition which can smooth fine lines and wrinkles, impart firmness and elasticity to the facial skin, and make fine lines and wrinkles less noticeable, all within a short period of time. The cosmetic composition is in a hydrogel form and contains sodium hyaluronate, modified cornstarch,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090041812 - Therapeutic calcium phosphate particles in use for aesthetic of cosmetic medicine, and methods of manufacture and use: Calcium phosphate (“CAP”) particles for use in cosmetic, nutraceutic or aesthetic medicine. The particles may be used as carriers for cosmetic, nutraceutic or a factors, as controlled release matrices for the material, and as fillers in cosmetic treatments. The particles may be applied topically or injected or by any other... Agent: Kenyon & Kenyon LLP

20090041817 - Water-in-oil type emulsion sunscreen cosmetics: The water-in-oil type emulsion sunscreen cosmetic in the present invention is characterized by comprising 0.2 to 10% by mass (a) octocrylene, 0.2 to 30% by mass (b) hydrophobized titanium dioxide and/or zinc oxide, 0.02 to 8% by mass (c) phenylbenzimidazole sulfonate, (d) a neutralizer for the above-mentioned component (c), and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090041818 - Antiviral agent, and fabric and antiviral member supporting antiviral agent: An antiviral agent having been experimentally supported which contains a powder obtained by baking (calcining) dolomite and hydrating a part thereof. Thus, it is possible to provide an antiviral agent which is usable in masks, filters, etc. because of acting directly on viral particles, thus eliminating the infectious capacity of... Agent: Kratz, Quintos & Hanson, LLP

20090041819 - Pesticidal composition: A coated pesticidal granule obtained by aggregating a powdery pesticide with a thermosetting resin is capable of enabling a pesticidal active ingredient to be controlled-released. Further, the controlled-release pesticidal granule can be produced by mixing a powdery pesticide with a first liquid component serving as a raw material for a... Agent: Foley And Lardner LLP Suite 500

20090041820 - Functional polymer compositions: Functional polymer compositions and methods of forming such compositions are provided. The functional polymer compositions include at least 50 wt % of one or more polymer components; from 0.1 to 50 wt % of one or more fluids; and from 1 to 50 wt % of one or more active... Agent: Exxonmobil Research And Engineering Company

20090041821 - Cleaner for medical probe: Cleaning of a medical probe is provided by a gel layer deposited on a carrier to form a cleaning element. The gel has a tacky surface and is impregnated with a disinfecting agent. After contacting the patient's body surface, the medical probe surface is cleaned by pressing it against the... Agent: Jacob Fraden Advanced Monitors Corp.

20090041822 - Tissue transplant construct for the reconstruction of a human or animal organ: e

20090041823 - Agent-releasing vascular prosthesis: The invention relates to a prosthesis comprising a proximal and a distal end and a hollow space that extends there-between. Said prosthesis is provided with a support structure and at least one biologically active compound.... Agent: Dykema Gossett PLLC

20090041825 - Cell culture well-plates having inverted colloidal crystal scaffolds: An artificial bone marrow construct comprising a substrate having at least one well; a three dimensional biocompatible polymer matrix comprising a transparent polymer network containing microspherical voids, wherein the microspherical voids are each connected to at least one other void through inter-connecting pores; at least one LBL coating on a... Agent: Harness, Dickey & Pierce, P.L.C

20090041824 - Method and apparatus for composite drug delivery medical devices: A medical device and method for drug delivery employing a 3-dimensional pattern of a polymer support material (e.g., that is degradable after implant in a body), a drug associated with the polymer support material, and an adhesive that adheres the polymer support material and associated drug to body tissue. The... Agent: Wolf Greenfield & Sacks, P.C.

20090041827 - therapeutic microfoam: Improved therapeutic sclerosing microfoams are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090041826 - Tissue implant and process for its production: The present invention relates to a process for producing an implant for medical purposes, to the implant obtainable by the process, and to the bioreactor used for the production of the implant. The implants of the invention can be used as implantable prostheses having essentially the functional characteristics of the... Agent: Greer, Burns & Crain

20090041828 - Insert for the treatment of dry eye: The invention relates to an insert for the treatment of dry eyes, wherein the insert can be placed on or inserted into the lacrimal sac or the cornea.... Agent: Dreiss, Fuhlendorf, Steimle & Becker

20090041829 - Pharmaceutical dosage forms comprising a lipid phase: A tablet for oral administration comprises a lipid phase, comprised to 80% by weight or more by a mixture of (a) triglyceride, (b) mono- or/and diglyceride, and (c) cell membrane lipid; (d) one or more pharmacologically active agents dissolved or dispersed in the lipid phase; (e) water and/or ethanol; and... Agent: Dickstein Shapiro LLP

20090041830 - Traumatic brain injury biomarker diagnostic: Blast Induced Traumatic Brain Injury or bTBI needs objective and subjective testing that can be made quickly in the field. Subjective tests using shapes, textures, tastes and odors as disposable, edible candies on a stick may be carried in a field kit. An objective test that employs a similar candy... Agent: Atk C/o Vidas, Arrett & Steinkraus, P.A.

20090041831 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.... Agent: Darby & Darby P.C.

20090041832 - Adhesive mixture for transdermal delivery of highly plasticizing drugs: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090041837 - Aptamers utilized as targeting agents for pharmaceutical compounds used in the treatment of cancer and other diseases: This invention describes a method whereby selected aptamers are used as a carrier compound to deliver drug nanoparticles and/or drug liposomes to the tumor or disease site. These aptamers have the propensity to localize in areas of tissue necrosis. Many tumors have areas of necrosis that can be targeted using... Agent: Henry John Smith

20090041833 - Composition comprising gas-filled microcapsules for ultrasound mediated delivery: Composition comprising gas filled microcapsules and a bioactive agent, useful for an ultrasound-mediated delivery of said bioactive agent. The microcapsules comprise a relatively stiff shell of polymeric or lipid material and have in particular a resistance to a mechanical index of at least 0.15, while the bioactive agent is substantially... Agent: Bracco Research Usa Inc.

20090041834 - Compositions and methods for treating lymphoma: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090041836 - Glycolipopeptide and uses thereof: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090041835 - Method of inhibiting leakage of drug encapsulated in liposomes: The present invention provides a method of inhibiting the leakage of a drug encapsulated in liposomes, which comprises satisfying at least two requirements selected from the group consisting of the following three requirements: using at least two lipid bilayers of the liposomes, controlling the average particle size of the liposomes... Agent: Fitzpatrick Cella Harper & Scinto

20090041838 - Anti-misuse microparticulate oral drug form: The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by... Agent: Patton Boggs LLP

20090041839 - Pharmaceutical compositions for the treatment of pain: The present invention provides pharmaceutical compositions comprising an allosteric adenosine A1 receptor enhancer, such as T-62, in an oral dosage form and processes for the manufacture of such compositions and dosage forms. In another aspect, the present invention relates to a method of employing such dosage forms for the treatment... Agent: King Pharmaceuticals, Inc.

20090041840 - Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration: A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary solid dosage, and prepared for oral administration before bedtime. Usually, structure is configured to initially release a calmative or other sleep-compatible substance by prompt... Agent: Robert F. Frijouf Frijouf, Rust & Pyle, P.A.

20090041841 - Controlled release tablet formulations for the prevention of arrhythmias: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more... Agent: Seed Intellectual Property Law Group PLLC

20090041842 - Partly neutralised anionic (meth) acrylate copolymer: The invention relates to a partly neutralised anionic (meth)acrylate copolymer consisting of radically polymerised units containing 25-95% by weight (meth)acrylic acid C1 to C4 alkylesters and 5-75% by weight (meth)acrylate monomer with an anionic group, wherein 0.1 to 25% contained anionic groups are neutralised by a base. Said invention is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090041843 - Pharmaceutical preparation having excellent photostability: The present invention relates to a pharmaceutical preparation of high photostability which contains pitavastatin, which is an HMG-CoA reductase inhibitor, a salt of pitavastatin, or an ester of pitavastatin. The pharmaceutical preparation contains a pitavastatin compound, titanium oxide, and a colorant having a maximum absorption wavelength of 400 nm to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090041844 - Modified release formulation: The invention is directed to the use of an extended release tablet formulation for pramipexole.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090041845 - Implantable medical devices having thin absorbable coatings: Disclosed herein is a coating having a layer that includes a matrix phase and a dispersed phase substantially immiscible in the matrix phase and methods of using the same.... Agent: Squire, Sanders & Dempsey LLP

20090041846 - Minocycline oral dosage forms for the treatment of acne: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.... Agent: Ohlandt, Greeley, Ruggiero & Perle,llp Medicis Pharmaceutical Corporation

20090041849 - Dissolution aids for oral peptide delivery comprising a biguanide: A pharmaceutical composition comprising a mixture of: (c) an active macromolecular principle; (d) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof; and (d) a biguanide or a pharmaceutically acceptable salt thereof, capable of... Agent: Nixon & Vanderhye, PC

20090041847 - Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions: wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted... Agent: Marshall, Gerstein & Borun LLP

20090041848 - Skin anti-aging agent for external use: It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises... Agent: Sughrue Mion, PLLC

20090041850 - Process for preparation of swellable and degradable microspheres: A process for producing microspheres was developed that provides microspheres that are swellable and degradable. The process is reliable and high yielding, and makes use of a low temperature azo initiator, a small molecule chlorinated solvent as the organic phase, and a heat treatment step, and is carried out in... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090041851 - Composition for the delivery of live cells and methods of use thereof: The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090041852 - Dry powder compositions and systems for poultry vaccination: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder... Agent: Clark & Elbing LLP

20090041853 - Therapeutic bio platinum complex: A novel bio platinum complex which increases the therapeutic applicability and effectiveness of platinum used as a cancer treatment in humans and animals especially in anti tumor treatments and to prevent the spread of cancer without fear of high toxicity. The present invention provides for a new method of administration... Agent: Alfred F. Hoyte, Esq.

20090041854 - Parathyroid and thymus transplantation in digeorge syndrome subjects: A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism.... Agent: Myers Bigel Sibley & Sajovec

20090041855 - Therapeutic agent for ophthalmic diseases: A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent... Agent: Birch Stewart Kolasch & Birch

20090041856 - Methods for promoting hair growth: The present invention relates to methods of promoting hair growth in a patient. The method comprises administering to a patient in need thereof a sugar compound that is converted to a glycosaminoglycan in the patient, a primary antioxidant component, at least one amino acid component, and one or more transition... Agent: Townsend And Townsend And Crew, LLP

20090041857 - Analgesic cream: A herbal topical composition is used having complexed trace minerals capable of effectively reducing bone and joint inflammation by inhibiting inflammation pathways and in particular COX-2. The herbal composition having trace elements in a topical carrier reduces inflammation while avoiding the side effects associated with traditional drug therapy.... Agent: Seyfarth Shaw LLP

20090041858 - Haemostatic compositions thickened by polymers containing nitrogen moieties: The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the... Agent: Geoffrey E. Dobbin, Patent Attorney

20090041859 - Wound treatment drugs for external use: [Means for solving problem] Preparation of a wound treatment drug for external use containing oily bases and iodine but substantially no white soft sugar, which is a characteristic of the drug of this invention. The invented drug prevents infection through the wound surface due to a sufficient bactericidal effect of... Agent: Warren M Cheek, Jr Wenderoth, Lind & Ponack, L.L.P.

20090041860 - Orally-dispersible pharmaceutical compositions: The invention relates to oral pharmaceutical compositions which take the form of orally-dispersible tablets containing calcium and, optionally, vitamin D and/or fluorine together with pharmaceutically-acceptable excipients and which can be used for the treatment or prevention of osteoporosis and other diseases characterised by loss of bone mass.... Agent: Sheridan Ross PC

20090041861 - Estrogen receptor alleles that are predictive of increased susceptibility to bone fracture: In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor α gene are present,... Agent: Sheridan Ross PC

20090041862 - Detecting disease association with aberrant glycogen synthase kinase 3beta expression: The present invention provides a method for diagnosing a disease or disorder associated with aberrant GSK-3β expression and/or activity or for determining the predisposition of a subject to the disease or disorder. In particular, the methods of the present invention comprise detecting a marker that comprises one or more polymorphisms... Agent: Pepper Hamilton LLP

20090041863 - Use of gsk3 inhibitors in combination with radiation therapies: The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090041866 - Abnormal protein removing composition: e

20090041864 - Apparatus and method for cellular extract enhancement: An apparatus 110 for increasing extracts 100E taken from cellular plant tissue 100 has a preparation container 114 for holding the cellular plant tissue 100, the container 114 having an inlet or opening 112 to receive a fluid 101 to wet the cellular plant tissue 100 and take extracts 100E... Agent: David L. King, Sr.

20090041868 - Binding and rinse-off of quaternary ammonium compounds for cosmetic and personal care applications: The disclosed composition and method includes the use of non-polar unsaponifiable material and polar hydrophilic salts in conjunction with quaternary ammonium compounds to provide hair treatment preparations for cosmetic and personal care applications. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to improve substantivity and/or... Agent: International Flora Technologies, Ltd. C/o Intellevate LLC

20090041867 - Estrogenic extracts of ligustrum lucidum ait. of the oleaceae family and uses thereof: Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF)... Agent: Wilson Sonsini Goodrich & Rosati

20090041865 - Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same: An extract of the family Dioscoreaceae useful for preventing or treating the peripheral neuropathy; and a pharmaceutical composition or food composition comprising the extract are provided. In addition, a pharmaceutical composition or food composition useful for preventing or treating the peripheral neuropathy comprising a compound isolated from the extract of... Agent: The Nath Law Group

20090041869 - Method of reducing insect resistant pests in transgenic crops: The present invention discloses Resistance Management (RM) practices that are critical to safeguard Bacillus thuringiensis as a natural resource and sustain genetically modified corn expressing Bt toxins as a suitable method for ECB and WCRW management. A useful tool in developing RM strategies is to develop laboratory selected colonies that... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pioneer Hi-bred

20090041870 - Annatto extract compositions including tocotrienols and tocopherols and methods of use: Compositions and methods of use of annatto extracts [350-450 Dalton molecular weight fraction] including tocotrienols and tocopherols with an appropriate spectrum. This spectrum includes but not limited to low alpha tocopherol, high delta- and gamma-tocols, and mixtures with other extracts [350-450 Dalton molecular weight fraction] like palm and rice and/or... Agent: Kirk Hahn

20090041871 - Composition for controlling the respiratory effect of inhaled pollutants and allergens: An oil-based composition for application to mucosal surfaces of the human body provides potent activators of cytoprotective antioxidants. The composition includes the following ingredients: soy oil; coconut oil; orange oil; peppermint oil; aloe vera oil; vitamin E; and may further include jojoba and a preservative. Application of the composition increases... Agent: Robert M. Downey, P.A.

20090041872 - Encapsulated vaccinium extracts with balanced gastrointestinal release: The invention relates to Vaccinium fruit extracts, related preparations, production methods and uses.... Agent: Connolly Bove Lodge & Hutz LLP

20090041873 - Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same: This invention provides a process for extracting a pharmaceutically active fraction from the foliage (leaves and stems) and/or roots of Rauvolfia vomitoria and the fruit of Citrus aurantium. In one aspect, the process requires extracting from a boiled tea of Rauvolfia vomitoria foliage and/or roots and Citrus aurantium fruit an... Agent: Foley & Lardner LLP

20090041874 - Karaya gum-based hydrophilic gel system for skin care: A hydrophile gel system for cosmetic and/or skin care applications. The gel system comprises a detachable carrier film and a hydrogel which contains at least 15 percent by weight of karaya gum and whose water content is less than 5 percent by weight.... Agent: D Peter Hochberg Co The Baker Building

20090041875 - Anti-wrinkle composition: There is provided a novel anti-wrinkle composition comprising one or more from among watercress, juniper, baizhu and coltsfoot extracts as active ingredients.... Agent: Foley And Lardner LLP Suite 500

20090041876 - Oil/fat-containing composition for suppression of carcinogenesis: The present invention relates to an oil/fat-containing composition for suppressing carcinogenesis, the composition including a solution produced by bringing a hydrophobic extract of licorice, which has been produced by bringing licorice into contact with an alcohol, into contact with an oil/fat. According to the present invention, there are provided an... Agent: Sughrue Mion, PLLC

20090041877 - Composition comprising growth factor of xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof: This invention provides a process of producing extract comprises growth-stimulation components from husks, kernels, leaves, fruit-stems, branches, stems, roots, seed's shells and barks and their applications. A use of composition comprising the extract from the husks, kernels, leaves, fruit-stems, branches, stems, roots, seed's shells and barks of Wenguanguo for stimulating... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090041878 - Extracts of passion fruit and uses therof: An extract of passion fruit is prepared. The extract has the effect of lowering blood pressure and serum nitric oxide levels in mammals. The extract also provides a hepatoprotective effect, as well as antioxidant and anti-inflammatory effects in mammals. A novel compound was identified in the extract and given the... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20090035215 - Radiofluorination: The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characerized by Formula II, wherein the moieties F, R1, R2, B1,2, Y1,2, Z1,2 and E have the meaning as... Agent: Millen, White, Zelano & Branigan, P.C.

20090035219 - Cb1 receptor antagonists and uses thereof: Neutral antagonists of the CB1 cannabinoid receptor, means for identifying neutral antagonists of the CB1 cannabinoid receptor, and uses thereof. Antagonists of the CB1 cannabinoid receptor can be used to prevent, treat or reduce the severity of various medical conditions and symptoms, including, but not limited to obesity, appetite disorder,... Agent: Alix Yale & Ristas LLP

20090035216 - Method for determining in vivo biopharmaceutical concentration or bioavailability: The invention provides a method for determining the bioavailability of single light chain bio-agents in biological samples. The method determines that bioavailability by utilising a labelled form of the bio-agent and incubating with a probe that binds for the alternative light chain antibody form as compared to the form of... Agent: Edwards Angell Palmer & Dodge LLP

20090035218 - Systems and methods for tissue imaging: The present invention provides systems and methods for monitoring tissue regions. In particular, the present invention provides systems and methods for detecting changes in tissue regions over a period of time. In some embodiments, the systems and methods of the present invention are used to evaluate the effectiveness of a... Agent: Casimir Jones, S.c.

20090035217 - Truncated fragments of alpha-synuclein in lewy body disease: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as... Agent: Townsend And Townsend And Crew, LLP

20090035220 - high throughput screening system and method: A high throughput screening method for determining the pharmacological effect of a given agent, the method comprising, providing an assay plate with at least one sample well, where at least one well contains a volume of media and at least one zebrafish, introducing at least one agent to at least... Agent: Italia Ip

20090035221 - Methods and compositions for treatment of erectile dysfunction: A dosage chart for the treatment of achieving and maintaining male erectile response regardless of state of mind, occurrence of ejaculation or lack of sexual arousal of an object. The chart including a general, physical, and psychological conditions of the object; an age of the object; at least one pharmaceutical... Agent: Baker & Hostetler LLP

20090035222 - Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence: Techniques for detecting fluorescence emitted by molecular constituents in a wall of a body lumen include introducing an autonomous solid support into the body lumen. Cells in a lumen wall of the body lumen are illuminated by a light source mounted to the solid support with a wavelength that excites... Agent: The Johns Hopkins Universityapplied Physics Labora Office Of Patent Counsel

20090035223 - Biomimetic iron-oxide-containing lipoprotein and related materials: An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090035224 - Methods of using albuterol and calcium activated potassium channel openers: This invention related to methods of treating, preventing and managing various pulmonary or respiratory diseases or disorders using albuterol in combination with calcium activated potassium channel openers. Pharmaceuticals compositions comprising albuterol and calcium activated potassium channel openers are also disclosed.... Agent: Jones Day

20090035225 - Rnai-related inhibition of tnfa signaling pathway for treatment of glaucoma: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk... Agent: Alcon

20090035226 - Use of cranberry extract enriched in total phenols and free, essentially free, or substantially free of sugars, acids, sulfur and other contaminants, for periodontal treatment: Cranberry and other plant extracts enriched in total phenols and free or substantially free of sugars, acids, sulfur and other contaminants are used for periodontal treatments. The periodontal treatments of the present invention include swish and swallow techniques, in which the extracts enriched in total phenols but free or substantially... Agent: Hogan & Hartson LLP

20090035227 - Confectionery products comprising a tooth-friendly sweetener: Confectionery products comprising a tooth-friendly sweetener, bioactive glass particles and at least one product additive, as well as processes for obtaining the products and various applications thereof.... Agent: Ostrolenk Faber Gerb & Soffen

20090035228 - Skin and surface disinfectant compositions containing botanicals: The present invention relates to a skin or surface disinfectant composition with broad spectrum antimicrobial activity comprising one or more essential oil (and/or one or more component thereof) and one or more fruit acid. The compositions of the invention may be used as non-toxic alternatives to conventional disinfectants or may... Agent: Baker Botts L.L.P.

20090035229 - Pharmaceutical composition for improving oral hygiene and methods thereof: An aqueous based pharmaceutical composition for use as a oral hygienic treatment is described. The composition contains a pharmaceutically effective amount of a tetracycline-based antibiotic; a water-soluble calcium salt that aids in solubilizing the tetracycline-based antibiotic; a thickener; a pH adjustment agent; an antifoaming agent; an excipient; a surfactant; a... Agent: Ladas & Parry LLP

20090035230 - Permanganate containing whitening compositions and methods of their use: In general, the invention provides a fast-acting, whitening composition containing permanganate. Particular alkali-metal or alkaline-earth metal salts of permanganate; hydrogen peroxide; or an alkali or alkaline-earth metal peroxide; and an acid.... Agent: Jonathan P. O'brien Miller Canfield Paddock & Stone

20090035231 - Topical oral composition: A topical oral composition in an orally acceptable carrier, the composition comprising: dehydroacetic acid, a peroxide source and optionally sodium lauryl sulfoacetate, gelling agents, flavors, and abrasives.... Agent: Meredith & Keyhani, PLLC

20090035232 - Fixed-dose association of phytate and zinc: The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10... Agent: Woodcock Washburn LLP

20090035234 - Continuous spray sunscreen compositions: The present disclosure generally relates to sunscreen compositions that are suitable for topical application to human skin and hair. More particularly, the disclosure relates to sprayable sunscreen compositions having improved water resistance and a low overall percentage of sunscreen actives. To achieve the improved water resistance, a dimethicone derivative is... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090035233 - Conversion of liquid formulations to a powder: A powdered composition comprising a liquid or semisolid formulation and a polymeric microparticle delivery system. The powdered composition is capable of converting to the liquid or semisolid composition upon application to a substrate, such as skin or a scalp.... Agent: Marshall, Gerstein & Borun LLP

20090035235 - Cosmetic composition for combating the cutaneous consequences of pollution: The invention relates to the use of the extracts of plants of the genus Lapsana and of the species Lapsana communis L (Asteraceae) in particular. Said extracts are preferably obtained by maceration in a hydroglycolic mixture, and are used in cosmetic or dermopharmaceutical preparations for their skin-protective and radical-resistant properties.... Agent: Harness, Dickey & Pierce, P.L.C

20090035236 - Emulsion cosmetic compositions containing resveratrol derivatives and an oil phase structuring agent: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase having at and at least one oil phase structuring agent, and a method for preparing emulsions capable of delivering active resveratrol to the skin.... Agent: Julie Blackburn

20090035237 - Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase, having at least one silicone surfactant, and a method for preparing emulsions capable of delivering active resveratrol to the skin.... Agent: The Estee Lauder Cos, Inc

20090035238 - Uv filter capsule containing an amino-substituted hydroxybenzophenone: The present invention relates to UV filter capsules comprising at least one aminosubstituted hydroxybenzophenone, to the use thereof for producing cosmetic or dermatological formulations and preformulations, and to cosmetic or dermatological formulations which comprise the capsules, and to methods for the production thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20090035240 - Aqueous based cosmetic compositions containing resveratrol derivatives and an aqueous phase structuring agent: An aqueous based cosmetic composition comprising at least one resveratrol derivative and a water phase containing at least one aqueous phase structuring agent; or an emulsion composition comprising at least one water phase, at least one oil phase containing at least one nonvolatile silicone, and at least one resveratrol derivative.... Agent: Julie Blackburn

20090035241 - Colouring composition for the skin comprising a self-tanning agent and a dye obtained by reacting an amine with dehydroascorbic acid or a monomeric polymeric or isomeric derivative thereof:

20090035239 - Eye-shadow and process for its preparation: New eye-shadow and process for the preparation thereof, characterised in that the conventional stage of preparation of the powder cake is followed by two further stages: an intermediate stage at which the cake is wetted with an oily compound, and a final stage at which the oily compound is absorbed.... Agent: Young & Thompson

20090035243 - Anhydrous cosmetic compositions containing resveratrol derivatives: An anhydrous color cosmetic composition comprising at least one resveratrol derivative and particulates; and an anhydrous emulsion skin care composition.... Agent: Julie Blackburn

20090035244 - Cosmetic composition comprising functionalised poly(alpha olefin-copolymer-maleic anhydride): A cosmetic composition is described comprising functionalised polyanhydrides, specifically functionalised poly(alphaolefin-copolymer-maleic anhydride) copolymers, thereafter also indicated as functionalised polyanhydrides. It is further described a process to prepare such a cosmetic composition by the functionalisation of the polyanhydrides by opening reactions of the anhydride ring with molecules containing at least one... Agent: Akerman Senterfitt

20090035242 - Emulsion cosmetic compositions containing resveratrol derivatives and linear or branched silicone: An emulsion cosmetic composition comprising at least one resveratrol derivative, a water phase, and an oil phase containing at least one linear or branched volatile or near volatile silicone and a method for delivering active resveratrol to the skin.... Agent: Julie Blackburn

20090035245 - Deodorant cosmetic composition comprising a combination of a lipophilic salicylic acid derivative and an antiperspirant aluminium salt: The present invention relates to a deodorant cosmetic composition comprising: (a) at least one lipophilic salicylic acid derivative of formula (I) below, or a salt thereof: (b) at least one antiperspirant aluminium salt; in an (a)/(b) weight ratio of less than 1/20. The invention also relates to a cosmetic process... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090035247 - Method of stabilizing a polysiloxane emulsion and compositions containing stabilized emulsions: A method of stabilizing an emulsion containing a polysiloxane and one or more surfactants comprising adding an effective amount of dispersion containing a DADMAC/acrylamide copolymer and one or more sulfate salts into said emulsion is disclosed. An emulsion/cosmetically acceptable emulsion comprising a polysiloxane, at least one surfactant, and a dispersion... Agent: Nalco Company

20090035246 - Long lasting and waterproof lash extension composition: Compositions and methods for the in situ formation of cross-linked polymeric filaments are disclosed. The disclosed filaments are preferably elastomeric, water-resistant, oil-resistant, long-wearing. The filament forming compositions generally comprise one or more cross-linkable polymers having at least one functional group capable of forming cross-links and a cross-linking agent, the presence... Agent: Joan M. Mcgillycuddy Avon Products, Inc.

20090035248 - Fast degrading polymers: The invention provides polyanhydrides that degrade in less than 60 hours following topical administration to deliver biologically active compounds.... Agent: Viksnins Harris & Padys Pllp

20090035249 - Method of inhibiting proliferation of escherichia coli: A method of inhibiting proliferation of Escherichia coli at an anatomical site on tissue of a human or animal body is described. The method comprises applying to the site a bacteriostatically effective amount of an aminated polyether.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090035250 - Compositions and methods for treating cavity conditions: Compositions, methods and kits to be used as a lubricant and for treatment of a cavity pathology including joint pathology are provided. The composition comprises therapeutically effective amounts of at least one bioactive agent, such as magnesium compound, at least one lubricating agent, such as hyaluronic acid, and at least... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20090035251 - Method of applying an injectable filler: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.... Agent: Knobbe Martens Olson & Bear LLP

20090035262 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20090035263 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20090035265 - Compositions and methods for targeted delivery of factors: The present invention relates to compositions and methods for targeted delivery of biologically-active factors, such as cytokines, growth factors, chemotherapeutic agents, nucleic acids, and therapeutic agents. The compositions of the present invention can be used to treat diseases and pathologies in organisms. Additionally the invention relates to methods and compositions... Agent: King & Spalding LLP

20090035255 - Conjugate for targeting of drug: Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumour growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as... Agent: Dann, Dorfman, Herrell & Skillman

20090035257 - Devices, compositions and methods for the protection and repair of cells and tissues: The present invention relates to compositions that reduce the extent of cellular and tissue damage in response to injury or disease. Methods of using the compositions to repair reperfusion injury, and structural tissue damage due to trauma, disease or aging are provided. Also provided are methods of using the compositions... Agent: Doyle, Kathryn Ph. D. Drinker Biddle & Reath LLP.

20090035260 - Enhanced nasal composition of active peptide: A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in... Agent: Standley Law Group LLP

20090035259 - Group a streptococcal vaccines: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response... Agent: Seed Intellectual Property Law Group PLLC

20090035261 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and hosT-cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences,... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090035254 - Il-21 variants: IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090035266 - Immunogenic peptides and methods of use: The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These... Agent: Klarquist Sparkman, LLP

20090035252 - Method of inducing a ctl response: Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level... Agent: Davis Wright Tremaine LLP/mankind Corporation

20090035258 - Methods of treating cancer by administering human il-18 combinations: The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090035256 - Mutant il-10: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological... Agent: Robins & Pasternak LLP

20090035253 - Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090035264 - Storage stable powder compositions of interleukin-4 receptor: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.... Agent: Nektar Therapeutics

20090035267 - Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus... Agent: Elmore Patent Law Group, PC

20090035269 - Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer: The invention relates to a method for the production of a pharmaceutical composition for treating cancer by combining Parapoxvirus ovis with at least one anticancer agent. The invention furthermore relates to a method for treating a patient afflicted with cancer comprising the administration of Parapoxvirus ovis in combination with at... Agent: Morrison & Foerster LLP

20090035268 - Tetrazolyl acyclic hepatitis c serine protease inhibitors: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the... Agent: Elmore Patent Law Group, PC

20090035270 - Combination therapy using anti-angiogenic agents and tnf alpha: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said... Agent: Millen, White, Zelano & Branigan, P.C.

20090035273 - Combination treatment method with interferon-tau: A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events.... Agent: Perkins Coie LLP

20090035272 - Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and... Agent: Elmore Patent Law Group, PC

20090035271 - Tetrazolyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090035274 - Treatment and/or prevention of cancer and/or arthritis: The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090035279 - Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma: The present invention relates to methods of diagnosing a susceptibility to an ocular disorder, including glaucoma and exfoliation syndrome. The invention provides methods of diagnosing an increased or decreased susceptibility to exfoliation syndrome and glaucoma, and methods for risk assessment, treatment and prognosis. The invention further relates to kits for... Agent: Marshall, Gerstein & Borun LLP

20090035277 - Hepatitis c virus nucleic acid vaccine: The present invention features nucleic acid constructs that can be used as a HCV nucleic acid vaccine, vaccine component, or in the production of a HCV vaccine. Described constructs include those: (1) encoding for a chimeric HCV polypeptide containing a NS3-4A region based on a first HCV strain and an... Agent: Merck And Co., Inc

20090035275 - Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad: Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in... Agent: Mcdermott Will & Emery

20090035276 - Use of a combination of myxoma virus and rapamycin for therapeutic treatment: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin... Agent: Wellstat Management Company. LLC

20090035287 - Atrial natriuretic peptide (anp) splice variants and methods of using same: Novel ANP polypeptides and polynucleotides encoding same are provided. Also provided are methods and pharmaceutical compositions which can be used to treat ANP-related diseases and disorders including cardiovascular disorders using the polypeptides and polynucleotides of the present invention.... Agent: Fennemore Craig

20090035288 - Edible product containing beneficial bacteria: The present invention provides a method of preparing an edible product comprising non-viable bacteria providing a health benefit, the method comprising subjecting viable bacteria to at least two sub-lethal treatments to obtain the non-viable bacteria providing a health benefit, each sub-lethal treatment on its own not being sufficient to render... Agent: Unilever Patent Group

20090035280 - Agrochemically active microbial formulation: The present invention provides an agrochemically active microbial formulation comprising a combination of an agrochemically active microbe with a specified ester compound and a surfactant, the formulation exhibiting a stable pest controlling effect with no harmful effect on a plant and having highly stable viability of the agrochemically active microbe... Agent: Sughrue Mion, PLLC

20090035281 - Combination of interleukin-6 antagonists and antiproliferative drugs: The combination of an interleukin-6 (IL-6) antagonist and an antiproliferative drug is described. In its preferred embodiment, the present invention describes the combination of an IL-6 superantagonist, particularly a superantagonist totally incapable of binding gp130 and an antiproliferative drug belonging to the glucocorticoid class (SANT-7 and dexamethasone). The combination according... Agent: Lucas & Mercanti, LLP

20090035283 - Composition and method for inhibition of melanin synthesis: The present invention provides a whitening cosmetic composition comprising a stem cell, a culture medium thereof or a protein isolated from the culture medium and a method of whitening a skin which comprises administering to the skin an therapeutically effective amount of a stem cell, a culture medium thereof or... Agent: Edwards Angell Palmer & Dodge LLP

20090035285 - Compositions and methods for enrichment of neural stem cells using ceramide analogs: The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from... Agent: Sutherland Asbill & Brennan LLP

20090035284 - Derivation of neural stem cells from embryonic stem cells and methods of use thereof: Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and... Agent: Sheppard, Mullin, Richter & Hampton LLP

20090035286 - Intracoronary, intracardiac, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium: The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either... Agent: Tca Cellular Therapy, LLC Attn: Vicki L. Nicely

20090035282 - Pluripotent embryonic-like stem cells derived from teeth and uses thereof: A stem cell which is obtainable from the non-embryonic tissue isolated from the dental follicle of tooth or wisdom tooth which are able to differentiate into a periodontal ligament like membrane structure.... Agent: Jacobson Holman PLLC

20090035289 - Dry platelet composition: The invention features a dry platelet composition and methods of making and using the freeze-dried platelet composition.... Agent: Fish & Richardson P.C.

20090035290 - Glycine n-methyltransferase (gnmt) animal model and use thereof: The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease.... Agent: Wpat, PC Intellectual Property Attorneys

20090035291 - Therapeutic use of adpase enhanced apyrases: The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.... Agent: Morrison & Foerster LLP

20090035292 - Use of phosphatases to treat neuroblastomas and medulloblastomas: Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand... Agent: Cooper & Dunham, LLP

20090035293 - Amylases for pharmaceutical use: The pharmaceutical use of amylases related to Bacillus alpha-amylases of SEQ ID NOs: 1-3, optionally in combination with a lipase and/or a protease. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The amylases of SEQ... Agent: Novozymes North America, Inc.

20090035294 - Lipopolysaccharide fractions of vitreoscilla filiformis useful for stimulating the synthesis of anti-microbial peptides of the skin: Specific fractions of Vitreoscilla filiformis comprising its Lipid A are useful for stimulating the synthesis of anti-microbial peptides of the skin.... Agent: Buchanan, Ingersoll & Rooney PC

20090035278 - Reoviruses having modified sequences: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.... Agent: Fish & Richardson P.C.

20090035296 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20090035300 - Immunomodulation of dendritic cells: The present invention relates to isolated nucleic acid molecule encoding the transcription regulator DC-SCRIPT or a derivative thereof. The invention further relates to its use in therapy and to compound for interfering with the biological function of the transcription factor DC-SCRIPT. Such compounds can be compounds interfering with expression of... Agent: Bozicevic, Field & Francis LLP

20090035299 - Methods and compositions for treating diseases targeting maba1: Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro.... Agent: Celera Corporation

20090035301 - Methods for diagnosing and treating bladder cancer: The present invention relates to the diagnosis and treatment of bladder cancer. More specifically, this invention uses the levels of macrophage migration inhibitory factor (MIF) produced by the bladder epithelia (urothelia) as a marker for bladder cancer. Moreover, the present invention also provides a method for attenuating bladder carcinoma by... Agent: Blank Rome LLP

20090035297 - Methods for treating diabetes: Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT1, in a subject by administering an inhibitor... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090035298 - Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders: The present invention provides methods for treating amyloid-beta accumulation-associated disorders, such as Alzheimer's disease. The methods comprise modulating the concentration of amyloid-beta in the brain interstitial fluid. In particular, the methods comprise modulating the activity of corticotrophin-releasing factor (CRF), which in turn modulates the concentration of amyloid-beta.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090035302 - Rage antagonists as agents to reverse amyloidosis and diseases associated therewith: Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE antagonists described herein may be used to... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20090035295 - Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies: The present invention is relates to non-diffusible globular Aβ(X-38 . . . 43) oligomers (“globulomers”) or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090035307 - Abeta conformer selective anti-abeta globulomer monoclonal antibodies: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.... Agent: Paul D. Yasger Abbott Laboratories

20090035310 - Cancer treatment: Pharmaceutical compositions and methods for inhibiting tumor growth and/or for inducing apoptosis are provided. Such compositions comprise at least one polypeptide of contiguous amino acids 1-198, 197-454, or 896-1150 of CARP-1 protein, and derivatives thereof, and may optionally comprise one or more cancer chemotherapeutic agents. Also provided are plasmids encoding... Agent: Davis Wright Tremaine, LLP/seattle

20090035305 - Compositions and methods for treating viral infection: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090035311 - Identification and use of prognostic and predictive markers in cancer treatment: The present invention provides a method of screening for markers useful in predicting the efficacy of the treatment of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow-up data; (b) labeling polynucleic acid probes specific... Agent: Vinson & Elkins L.L.P.

20090035308 - Methods for using and identifying modulators of delta-like 4: In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (Dll4) signaling.... Agent: Ropes & Gray LLP

20090035303 - Methods of detecting methyl transferase activity and methods of screening for methyl transferase activity modulators: The invention features a method for determining methyl transferase activity of a polypeptide and screening for modulators of methyl transferase activity. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer or hepatocellular carcinoma using the modulator.... Agent: Townsend And Townsend And Crew, LLP

20090035306 - Quinazolinone modulators of tgr5: The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090035309 - Substituted benzazoles and methods of their use as inhibitors of raf kinase: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as... Agent: Novartis Institutes For Biomedical Research, Inc.

20090035304 - Use of tgf-beta antagonists to limit nephrotoxicity of immunosuppressive agents: The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-β such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090035312 - Tumor angiogenesis associated genes and a method for their identification: Methods of identifying specific target molecules for design of anti-angiogenic and vascular targeting approaches are disclosed. Transcriptional profiles of tumor endothelial cells were compared with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as... Agent: Knobbe Martens Olson & Bear LLP

20090035313 - Compounds: t

20090035314 - Method and pharmaceutical composition for preventing or treating diseases associated with inflammation: The present invention relates to a method and pharmaceutical composition for preventing or treating inflammatory diseases. More particularly, the present invention relates to a method for inhibiting lymphocyte adhesion to an endothelial cell, or a method for treating an inflammatory disease, which comprises administering to a subject in need thereof... Agent: Buchanan, Ingersoll & Rooney PC

20090035315 - Method of improving treatments in rheumatic and arthritic diseases: Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds... Agent: Jones Day

20090035316 - Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc): The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease.... Agent: Morgan & Finnegan, L.L.P.

20090035318 - Method and composition for increasing the engraftment efficiency of stem cells: A method is described for increasing the engraftment efficiency of S/G2/M phase stem cells, which involves treating a recipient with the stromal cell-derived factor-1 (SDF-1) antagonist SDF-1G2 prior to delivery of the cells to said recipient. Further, a method of transplanting proliferating or S/G2/M phase stem cells is described, comprising... Agent: Borden Ladner Gervais LLP Anne Kinsman

20090035317 - Peptides binding to vascular endothelial growth factor: The invention relates to peptides that bind to vascular endothelial growth factor (VEGF). The invention further relates to methods of screening for VEGF-binding peptides, methods of using VEGF-binding peptides to detect the presence of VEGF in a biological sample, and methods of using VEGF-binding peptides to modulate VEGF activity and... Agent: Robins & Pasternak

20090035319 - Antibodies against c3a receptor: The present invention relates to antibodies and related molecules that specifically bind to C3a Receptor. Such antibodies have uses, for example, in the prevention and treatment of asthma, allergy, and other related inflammatory and immune disorders. The invention also relates to nucleic acid molecules encoding anti-C3a Receptor antibodies, vectors and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090035320 - Agents for regulating liver regeneration/repair: The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI... Agent: Fish & Richardson PC

20090035322 - Human antibodies to human cd20 and method of using thereof: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human... Agent: Regeneron Pharmaceuticals, Inc

20090035321 - Intercellular adhesion molecules and their binding ligands: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090035323 - Immune response modifier conjugates: The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.... Agent: 3m Innovative Properties Company

20090035324 - Novel pyrimidinecarboxamide derivatives: This disclosure relates to novel HIV integrase inhibitors their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating HIV infections.... Agent: Fish & Richardson P.C.

20090035325 - Canine influenza virus and related compositions and methods of use: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical... Agent: Barnes & Thornburg LLP

20090035326 - Compositions with antigens adsorbed to calcium phosphate: Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a... Agent: Novartis Vaccines And Diagnostics Inc.

20090035327 - Antibody gene transfer and recombinant aav therefor: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.... Agent: Marshall, Gerstein & Borun LLP

20090035328 - Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, using vesicle vaccines made from Neisseria strains have decreased or no detectable expression of a product of LpxL1 gene, and which optionally overexpress fHbp.... Agent: Bozicevic, Field & Francis LLP

20090035329 - Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions: The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods... Agent: Darby & Darby P.C.

20090035330 - Vaccine composition comprising b-subunit of e. coli heat toxin and an antigen and an adjuvant: The present invention provides a vaccine composition comprising the B-subunit of E. coli heat labile toxin or a derivative thereof with equal or greater than 90% homology complexed with an antigen and an adjuvant.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090035332 - Pharmaceutical formulation: This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, and one or more suitable pharmaceutical excipients, wherein the composition is coated with a coating comprising polyvinyl alcohol.... Agent: Duane Morris LLP - Ny Patent Department

20090035331 - Systems and methods for targeted and controlled delivery of agents: An Agent Delivery System allows for targeted and controlled delivery of an agent or agents to target site, such as specific cells or a specific tissue of an individual. An exemplary Agent Delivery System includes a platform, having a silica crystal lattice base plate, coated with a collagen-containing layer. At... Agent: Stites & Harbison, PLLC

20090035335 - Cosmetic composition containing a polymer blend: The present invention relates to a cosmetic composition containing a unique polymer blend, which includes: (a) a first polymeric film-former having a first glass transition temperature ranging from about −20° C. to about 0° C.; (b) a second polymeric film-former having a second glass transition temperature that is at least... Agent: Mimi Yang

20090035333 - Cosmetic skin preparation: A cosmetic skin preparation containing a porous powder which contains water absorbed therein and whose surface is coated with a binder containing a crosslinked type organopolysiloxane.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090035337 - Fluid reservoir: Fluid reservoirs which are based on polymer substrates and are capable of storing large amounts of fluids. The storage is reliable and the reemergence from the liquid reservoir is readily controllable, for example, via the temperature or via mechanical actions, to achieve retardation of the fluid release. Also, processes for... Agent: Ratner Prestia

20090035338 - Inverse emulsions comprising avermectins and cosmetic/dermatological applications thereof: Physically and chemically stable, oxidation-resistant, cosmetic/dermatological inverse emulsions contain a therapeutically effective amount of at least one avermectin compound, notably ivermectin, a glycolic or aqueous/glycolic dispersed hydrophilic phase, a continuous lipophilic phase and an emulsifier having an HLB ranging from 2 and 7, and are useful for the treatment of... Agent: Buchanan, Ingersoll & Rooney PC

20090035336 - Isoflavone nanoparticles and use thereof: The present invention is directed to isoflavone nanoparticle compositions comprising isoflavone in the form of nanoparticles and preferably a carrier. The isoflavone nanoparticle compositions are particularly useful for preparing cosmetic compositions, pharmaceutical compositions, foodstuff, food and feed additives. In the compositions comprising the isoflavone nanoparticle compositions recrystallization of the isoflavone... Agent: Nixon & Vanderhye, PC

20090035334 - Method for preparing polymethylmethacrylate spherical bead: This invention provides a method for preparing a polymethylmethacrylate spherical bead and in particular, it provides a method for preparing a polymethylmethacrylate spherical bead characterized in that it is prepared by preparing polymethylmethacrylate by polymerizing methyl-methacrylate monomers, evaporating remaining methylmethacrylate monomers by raising temperature up to at least 100° C.... Agent: Cantor Colburn, LLP

20090035339 - Methods of inactivating viruses: A method of inactivating viruses is provided. The method comprises the step of topically applying an antimicrobial composition comprising: an organic acid; and an anionic surfactant mixture having a characteristic selected from the group consisting of: a linear alkyl chain having a chain length of from about C4 to about... Agent: Brinks Hofer Gilson & Lione

20090035340 - Preservative compositions for moist wipes: The present disclosure generally relates to a composition for use with personal care products. The composition comprises a preservative system comprising methylisothiazolinone and a benzoic acid salt or derivative thereof. The weight ratio of methylisothiazolinone and benzoic acid salt in the composition is from about 1:30 to about 1:100. Also... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090035341 - Coating material: The invention relates to an antimicrobial and preferably non-cytotoxic coating material and to use of said coating material.... Agent: Alston & Bird LLP

20090035342 - Antimicrobial devices and compositions: The present invention comprises methods and compositions for antimicrobial devices comprising metal containing compositions which are resistant to heat and light discoloration. The metal containing compositions may comprise salts or complexes of silver, copper or zinc. In one aspect the compositions comprise silver salts. In another aspect, the compositions comprise... Agent: Troutman Sanders LLP

20090035343 - Delivery of dry formulations of octreotide: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.... Agent: Foley And Lardner LLP Suite 500

20090035349 - Composite scaffolds and methods using same for generating complex tissue grafts: A composite scaffold for engineering a heterogeneous tissue is provided. The composite scaffold includes: (a) a first scaffold being capable of supporting formation of a first tissue type thereupon; and (b) a second scaffold being capable of supporting formation of a second tissue type thereupon; wherein the first scaffold and... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090035348 - Dissolution of arterial plaque: Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in... Agent: Mcdermott Will & Emery LLP

20090035347 - Isolated stromal cells and methods of using the same: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent... Agent: Seed Intellectual Property Law Group PLLC

20090035344 - Multi-polymer hydrogels: The invention provides a multi-polymer hydrogel article having a first polymeric, water-swellable material and a second polymeric material, organized such that a first region substantially comprises the first polymeric, water-swellable material, a second region adjacent the first region comprises a mixture of the first polymeric, water-swellable material and the second... Agent: Wood, Herron & Evans, LLP (zimmer)

20090035345 - Nuclear receptors agonists for treatment of atherosclerosis and/or related cardiovascular disease: The invention relates to the use of an agonist of one or more of the nuclear receptors TR3, MINOR and NOT for the preparation of a medicament for the treatment of cardiovascular disease, in particular in-stent restenosis and/or vein-graft disease. The invention further relates to medical devices, such as stents... Agent: The Webb Law Firm, P.C.

20090035346 - Nuclear receptors agonists for treatment of atherosclerosis and/or related cardiovascular disease: Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state... Agent: K&l Gates LLP

20090035350 - Polymers for implantable devices exhibiting shape-memory effects: The present invention is directed to polymeric compositions comprising a biodegradable copolymer that possesses shape-memory properties and implantable devices (e.g., drug-delivery stents) formed of materials (e.g., a coating) containing such compositions. The polymeric compositions can also contain at least one non-fouling moiety, at least additional biocompatible polymer, at least one... Agent: Squire, Sanders & Dempsey LLP

20090035351 - Bioabsorbable hypotubes for intravascular drug delivery: A biodegradable implantable device for delivering a drug to a treatment site includes a biodegradable hypotube defining a lumen and at least one drug disposed within the lumen of the hypotube. At least one drug is released from the lumen upon degradation of the biodegradable hypotube. The lumen may be... Agent: Medtronic Vascular, Inc.IPLegal Department

20090035352 - Drug delivery particle: A drug delivery particle including a reservoir region having primarily large pores and a metering region. The particle can be highly spherical.... Agent: Fish & Richardson PC

20090035353 - Non-absorbent articles containing additives: Non-absorbent articles containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachloroprene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090035354 - Device and method for treating the anal sphincter: A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient... Agent: Martin D Moynihan Prtsi Inc

20090035355 - Confectionery products and process for obtaining them: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.... Agent: Ostrolenk Faber Gerb & Soffen

20090035356 - Modified biodegradable polymers, preparation and use thereof for making biomaterials and dressings: The invention concerns a method for preparing a modified biodegradable polymer in aqueous medium comprising at least two steps. The first step is a reaction between an amino acid, a peptide or a polypeptide and maleic anhydride to form a compound having an unsaturated vinyl-carboxylic acid function. In the second... Agent: Choate, Hall & Stewart LLP

20090035357 - Method of drug delivery using a transdermal device having a phase change material: A method of drug delivery utilizes a transdermal device that contains a phase change material and a first material such as a drug, a pharmaceutical, or a medicament mixed with or disposed near the phase change material. The phase change material is one that transitions from solid to liquid form... Agent: Terrance A. Meador Incaplaw

20090035361 - Composition for vaginal use: Compositions for vaginal use comprising lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and/or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the... Agent: The Firm Of Hueschen And Sage

20090035362 - Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss: The present invention includes methods and compositions useful for treating and preventing skin disorders, hair loss and other skin disorders. The compositions include an ARD enhancer in combination with a second compound or composition. In some embodiments the second compound is at least one of a bactericide, an antibiotic, an... Agent: David R Preston & Associates Apc

20090035359 - Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom: The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding... Agent: Fennemore Craig

20090035360 - Lyophilised antigen composition: The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090035364 - Para-substituted 2-alkoxyphenol compounds: Para-substituted 2-alkoxyphenols having cooling properties of formula (I) wherein R1 is methyl or ethyl; Y is, NH, O or S; R2 and R3 are independently of each other hydrogen or C1-3 alkoxy; n is 0 or 1; and the dotted line between C-2 and C-2′ represents at least one of... Agent: Curatolo Sidoti Co., Lpa

20090035358 - Phosphatidyl oligoglycerols: In order to form liposomes with a longer half-life in blood, use is made of defined compounds with the general formula (A)... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090035363 - Photoactive compounds and compositions and uses thereof: Photoactive compounds and compositions, as well as methods of using the same. For example, compositions of the invention may be used in Type 1 phototherapy, Type 2 phototherapy, or a combination of Types 1 and 2 phototherapy.... Agent: Mallinckrodt Inc.

20090035365 - Density controlled capsule particles and methods of making the same: The present invention discloses density controlled capsule particle and methods for making the same for use in a wide range of consumer and personal care products.... Agent: International Flavors & Fragrances Inc.

20090035366 - Nanoparticulate benzothiophene formulations: The present invention is directed to benzothiophene compositions, preferably nanoparticulate raloxifene hydrochloride compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the raloxifene hydrochloride nanoparticulate composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090035367 - Controlled degradation of expandable polymers in gastric volume reduction treatment: Orally administrable polymer-carrying units for expanding in a stomach of a mammal to fill a space in the stomach, the polymer-carrying units including: a carrier; a plurality of polymer molecules expandable in aqueous solutions, releasably coupled to the carrier; and means for selectively decoupling the polymer molecules from the carrier... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20090035368 - Embedded micellar nanoparticles: The present invention relates to a thermostable solid composition containing nanosized micelles, the micelles containing a poorly soluble chemical substance, such as a biologically active substance, dissolved in an auxiliary material, and the micelles being embedded in a water soluble carrier. The invention further relates to a process for preparing... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090035369 - Composition and methods for treating and preventing age-related macular degeneration: The present invention relates to methods and compositions effective in preventing, attenuating, inhibiting the progression of, and treating eye diseases, e.g., age-related macular degeneration (AMD). The compositions comprise, as an active ingredient, an effective amount of 3,3′-diindolylmethane (DIM) and/or its precursor indole-3-carbinol (I3C). The compositions can further comprise additional agents... Agent: Nixon & Vanderhye, PC

20090035370 - Dosage form and method of use: A method for treating a medical condition for which quetiapine is indicated in a subject comprises comprising orally administering to the subject quetiapine or a pharmaceutically acceptable salt thereof in a daily dosage amount effective to treat said condition; wherein the quetiapine or salt thereof is administered in one to... Agent: Kv Pharmaceutical Company

20090035371 - Tablet with remedial composition and methods for treating medical disorders and ailments: The invention discloses a pharmaceutical composition useful for treatment and prevention of medical disorders and ailments. The aforesaid composition comprises active ingredients comprising; Turmeric extract, Turmeric powder, optionally, Selenium or source of Selenium, especially Selenomethionine, optionally, Green tea extract. The pharmaceutical composition further comprises enteric coating encapsulating the same. The... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090035372 - method for manufacturing a pharmaceutical composition for controlled release of an active substance: e

20090035374 - Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same: The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and 0.030 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, of 2.0 mg of dienogest and... Agent: Striker, Striker & Stenby

20090035373 - Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same: The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, or 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with at least... Agent: Striker, Striker & Stenby

20090035375 - Pharmaceutical compositions for acute glucocorticoid therapy: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting.... Agent: Thorpe North & Western, LLP.

20090035376 - Stem cells obtained from pulp of deciduous or permanent teeth and of dental germ, able to produce human bone tissue: In this invention is described a method that foresees the isolation of a new subpopulation of stem cells derived form dental pulp, whose differentiation is osteoblasts lead to the subsequent production and employment of a bone tissue, called LAB (Living Autologous Bone). Specifically, the invention describes: 1) the isolation of... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090035377 - Composition and method for controlling drug delivery from silicone adhesive blends: Compositions and methods for controlling transdermal drug delivery, particularly of amine-functional and basic drugs, comprising a blend of a first silicone-based polymer having a reduced silanol concentration and a second silicone-based polymer have a substantial or high silanol concentration. The blend of such silicone-based polymers, particularly pressure-sensitive silicone adhesives, provides... Agent: Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq.

20090035379 - Fenofibrate compositions: The invention provides fenofibrate compositions comprising granulates, where the granulates comprise micronized fenofibrate.... Agent: Venable LLP

20090035378 - Nanostructured bioactive materials prepared by dual nozzle spray drying techniques: Nano-particles of calcium and phosphorous compounds are made in a highly pure generally amorphous state by spray drying a weak acid solution of said compound and evaporating the liquid from the atomized spray in a heated column followed by collection of the precipitated particles. Hydroxyapatite (HA) particles formed by such... Agent: Banner & Witcoff, Ltd.

20090035380 - Oil formulations: There is provided a composition comprising an oil medium, wherein particles are suspended in said oil medium, wherein said particles comprise cyclopropene and molecular encapsulating agent, and wherein said particles have median size, as measured by the largest dimension, of 50 micrometer or less. Also provided are a method of... Agent: Rohm And Haas Company Patent Department

20090035381 - Electrospraying method for fabrication of particles and coatings and treatment methods thereof: Electrospray systems and modified electrospray systems for the fabrication of core-shell particles for controlled-release and/or sustained-release treatment and delivery are herein disclosed. The electrospray system may include between one and a plurality of co-axially situated tubes. Each tube may be electrically connected to a power supply wherein a voltage may... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090035382 - Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound: Method for the treatment of articular diseases or articular pain, or for the treatment of skin, which comprises the infiltration or the application of a compound that comprises at least one blood-derived substance, which is preferably a blood plasma in general, and in particular a platelet-rich plasma (PRP), and preferably... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090035383 - Scavenger of in vivo harmful reactive oxygen species and/or free radicals: An object of the present invention is to provide a scavenger of in vivo harmful reactive oxygen species and/or free radicals, which is capable of effectively reducing the concentrations of in vivo reactive oxygen species and/or free radicals and exhibiting given effects such as the suppression of aging process, the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090035384 - Process for producing coated urea-formaldehyde polymers: The present invention relates to novel urea-formaldehyde polymers coated with an active ingredient, a method of making the same, and their use.... Agent: Albemarle Corporation Patent Department

20090035385 - Compositions including iron: Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an... Agent: Kv Pharmaceutical Company

20090035386 - Conditioning of a patient's blood by gases: The present invention relates to a method for using gas exchange modules for adjusting a pH value of blood in order to, e.g., adjust a non-physiological pH in patients treated with drugs whose activity optimum is in a non-physiological pH or to bring the pH to a physiological value.... Agent: Harness, Dickey & Pierce, P.L.C

20090035387 - Process for making ozonized olive oil gel and the gel obtained: A process for making oil which is rich in ozone in the form of a gel comprises the steps of introducing olive oil in liquid form and ozone into a reaction chamber; in which during the contact step there is a step of controlled cooling of the reaction chamber in... Agent: Pearne & Gordon LLP

20090035388 - Antimicrobial photo-stable coating composition: The invention is an antimicrobial photo-stable coating composition that deters photo-induced discoloration, does not stain tissue and can be applied to the surface of a variety of medical materials. The composition comprises in an aspect silver-PCA complex and dye.... Agent: Knobbe Martens Olson & Bear LLP

20090035389 - Targeted protein cages: The present invention provides targeted protein cages for the specific delivery of a variety of agents to cells and tissues and methods of use. The targeted protein cages have exterior targeting moieties and therapeutic or imaging agents which are encapsulated within the protein cages or are located on the exterior... Agent: Townsend And Townsend And Crew, LLP

20090035390 - Compositions containing zinc salts for coating medical articles: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.... Agent: Baker Botts L.L.P.

20090035391 - Nasal irrigation solutions and methods of using same: A nasal irrigation solution comprising is disclosed comprising water and hydrastine extracted from one or more plants. Another solution comprises water and berberine extracted from one or more plants. These solutions are provided from an extract of goldenseal plant. Solutions are also disclosed having canadine, canadaline, and hydrastidine, all extracted... Agent: Banner & Witcoff, Ltd.

20090035392 - User-adjustable treatment methods, systems and compositions for treating acne: Methods, apparatus, systems and the like for treating acne vulgaris that improves treatment effectiveness and/or reduces bothersome side effects associated with the ingredients used. The present Methods, apparatus, systems, etc., also provide topical compositions of benzoyl peroxide and/or other anti-acne agents that are useful for treating acne vulgaris and may... Agent: Graybeal Jackson LLP

20090035393 - Fast acting inhibitor of gastric acid secretion: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast... Agent: Coleman Sudol Sapone, P.C.

20090035394 - Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies: This invention relates to the finding that inhibition of the catalytic subunit of DNA protein kinase (DNA-PKcs) increases the sensitivity of cancer cells that display an ATM deficient phenotype to DNA damaging therapies, such as irradiation or chemotherapy. Methods of treating cancers displaying an ATM deficient phenotype and methods of... Agent: Bozicevic, Field & Francis LLP

20090035396 - Novel reference plant, a method for its production, extracts obtained therefrom and their use: The reference plant can be used to generate a reference extract with a reference chemical profile which resembles that of the comparator plant less the active compound or group of compounds and may thus be used as a placebo or to otherwise test the hypothesis that the active compound or... Agent: Wolf Greenfield & Sacks, P.C.

20090035395 - Spondias mombin l. extract and methods of extracting and using such extract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Spondias mombin L. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract... Agent: Cox Smith Matthews Incorporated

20090035397 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: Compositions and related methods of Cissus quadrangularis plant extracts and soy albumin that improve various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. In one exemplary embodiment, university studies demonstrated that a formulation of 300 mg Cissus quadrangularis plant extract, 3 mg niacin-bound chromium, 500 mg of... Agent: Kathryn P.wilke C/o Gaw Van Male

20090035398 - Topical formulations: A topical formulation includes at least about 45% by weight shea butter, hemp oil in an amount not greater than 40% by weight, almond oil in an amount not greater than about 15% by weight, and jojoba oil in an amount not greater than about 15% by weight.... Agent: Larson Newman Abel & Polansky, LLP

20090035399 - Yeast fermentation of rice bran extracts: Heat-stabilized defatted rice bran (HDRB) is fermented with yeast to afford a food product having superior prebiotic for probiotic properties. Fermentation of HDRB with yeast yields a prebiotic composition that can promote the growth and/or activity of beneficial intestinal bacteria (probiotic) when consumed by an animal or human. The prebiotic... Agent: James H. Meadows And Medicus Associates

20090035400 - Water dispersible compositions and methods of using the water dispersible compositions: Described herein are compositions comprising a nematicide intermixed with lecithin and a co-surfactant that form stable dispersions in water. Also disclosed are methods of controlling nematodes in soil by application of such compositions.... Agent: Archer Daniels Midland Company

20090035401 - Composition and method for inhibiting herpesviridae infections: The present invention relates to a pharmaceutical composition when used for inhibiting a herpesviridae infection and/or providing relief from a herpesvindae infection in a subject. The composition includes an effective amount of an extract from a plant in the Asteraceae family.... Agent: Nixon Peabody LLP - Patent Group

20090035402 - Method for extracting plants of the genus pelargonium, extract produced according to said method, and use thereof: The present invention relates to a process for the extraction of plants, especially roots, of the plant genus Pelargonium, characterised in that the plants are extracted with an ethanol-free solvent or a mixture of ethanol-free solvents, selected from the group consisting of water and at least one monohydric alcohol with... Agent: Miller, Matthias & Hull

20090035403 - Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof: Disclosed herein a herbal anticancer agent comprising the extract of plant Sphaeranthus indicus or group of compounds obtained from the plant Sphaeranthus indicus. The present invention also discloses a pharmaceutical composition comprising the said agent, methods for preparing the composition and methods of treating all kinds of cancer in mammals... Agent: Darby & Darby P.C.